Diabetes Connections | Type 1 Diabetes

It's "In the News.." got a few minutes? Get caught up! Top stories this week: The US Senate may have a bipartisan plan to lower the price of insulin for the insured, nasal insulin is tested to reduce the risk of Alzheimer's in people with diabetes, two interesting studies about sleep and diabetes, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Two Senators have unveiled legislation aimed at lowering the cost of insulin, but not for the uninsured. This is a bipartisan bill that would lower patietn's cost to 35-dollars a month, for those with commercial insurance and on Medicare. It would eliminate the rebates drug companies pay to negotiators known as pharmacy benefit managers if the drug company kept the overall price of insulin below a certain level. Democrats are also in the midst of talks on a party-line package on President Biden's economic agenda that would likely include reductions in insulin costs as well as broader measures aimed at lowering drug prices, which could complicate any push for a stand-alone insulin measure. This change has enormous support among Americans, but can't seem to get any real traction in Washington despite who's in power. We'll see what happens.. https://thehill.com/policy/healthcare/3531954-bipartisan-pair-of-senators-unveils-bill-to-lower-insulin-costs/ XX Nasal insulin doesn't look like it works too well on diabetes, but a new study shows it may help to slow age related mental decline. This study found that after 12 months of once daily intranasal insulin, people with diabetes in the study performed better on cognitive tests than those diabetics in the placebo group. The non-diabetic group receiving the intranasal insulin also displayed improvements on decision making and verbal memory tests compared to non-diabetics in the placebo group. The biggest improvements in the non-diabetic group were seen in those subjects who started the trial in a prediabetic state. This suggests the treatment may be most effective at slowing cognitive decline in either diabetics or those with prediabetes. https://newatlas.com/health-wellbeing/insulin-nasal-spray-cognitive-decline-dementia-clinical-trial/ XX Go to sleep, and don't breathe too much. Researchers in the U.K. will test hypoxia to treat type 2 diabetes. Hypoxia is a state where the body does not receive sufficient amounts of oxygen. Multiple studies have shown that hypoxia improves blood sugar levels and aids in weight loss. Although scientists do not fully understand how this works, it is suggested that hypoxia burns more calories in the body, resulting in lower appetites in individuals. These researchers want to recruit volunteers so they can figure out why. Each volunteer will be provided with a sleeping tent in which they have to sleep – at home - for 10-day periods on two separate occasions. For one of they nights, they oxygen levels will be set to 15 percent. That sounds ridiculous, but, the air we breathe right now is only about 21% oxygen. 15-percent is pretty typical for find at high altitudes or inside an airplane. https://interestingengineering.com/lose-weight-while-asleep XX Another look at sleeping and type 2.. an exposure to light may increase the risk. Big sleep study at Northwestern University found that exposure to any amount of light during the sleep period was correlated with the higher prevalence of diabetes, obesity and hypertension in both older men and women. A study published earlier this year by the same team found for healthy adults in their 20s. Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate. An elevated heart rate at night has been shown in prior studies to be a risk factor for future heart disease and early death, while higher blood sugar levels are a sign of insulin resistance, which can ultimately lead to type 2 diabetes. Instead of pulling people into a sleep lab, the new study used a real-world setting. Researchers gave 552 men and women between the ages of 63 and 84 an actigraph, a small device worn like a wristwatch that measures sleep cycles, average movement and light exposure. Fewer than half of the adults in the study got five hours

Wearing an insulin pump can be a huge help when it comes to managing diabetes, but finding a place to put it can be difficult. Women's clothing in particular, isn't great for storing stuff. Erin Calhoun-Dulaney has lived with type 1 for 40 years and she finally got fed up enough to create her own product. We'll talk about Skirt my Pump, her experience with T1D and her career as a Hollywood publicist. Stacey also has information about Tandem's Mobile Bolus limited roll out. Click here to find out more and sign up. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News.." got a few minutes? Get caught up! Top stories this week: Tandem Diabetes announces a limited launch of their mobile bolus feature (signup below), researchers look at how Basaglar stacks up, new guidelines for diabetes in the hospital, a T1D extreme athlete bikes across the USA and more Learn about the T1D Exchange! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Tandem's mobile bolus feature is in limited release. Approved earlier this year, they've released the feature to a very small number of users and are expecting a wider, still limited, release in the next few weeks. This is the feature that allows you to bolus by phone and use the t-connect app to see pump data on your phone as well. It's not full pump control via phone, but it's a big step forward in terms of convenience for users and for Tandem' next product, the MOBI pump – which won't have a screen and will have full phone control. I'm asking Tandem to come on the show and share more about the features and how it works. It's interesting that you can't dismiss alerts and alarms from the app and must do so on the pump itself. I'll link up the site you need to sign up for the limited release. You will need to update the software on your tslim x2 pump and take some additional online training. This is US only. https://www.tandemdiabetes.com/landing-pages/remote-bolus XX The Eversense E3 gets European approval. This is a partnership between Ascensia diabetes care and Senseonics. The E3 is the six month version of the implantable CGM system. It's also approved for insulin treatment decisions, which is a switch from the XL version already available in Europe. The E3 was approved in the US earlier this year and should be distributed in Europe in the fall. https://finance.yahoo.com/news/ascensia-diabetes-care-announces-european-060000125.html XX XX New guidelines for treating diabetes in the hospital. This is from the Endocrine Society, which last updated their guidelines ten years ago. New this time around, hospital use of continuous glucose monitoring and insulin pump therapy, providing inpatient diabetes education as part of a comprehensive diabetes discharge-planning process, use of noninsulin glucose-lowering therapies, and more. Adult patients with diabetes or newly recognized hyperglycemia account for greater than 30% of noncritically ill hospitalized patients. https://www.clinicaladvisor.com/home/topics/endocrinology-information-center/endocrine-society-issues-new-guidelines-for-hospitalized-patients-with-diabetes/ XX Works just as well and costs less.. that's the upshot of a new study on Basaglar, the copycat insulin to Lantus when it comes to type 2 diabetes. The findings come from 14 commercial health plans and Medicare Advantage plans. Basaglar was approved as a biosimilar insulin glargine by the US Food and Drug Administration in 2015. This was a large study of thousands of patients and also showed that there was better adherence to Basaglar, no reason for that was given, but it could be the lower cost. https://www.medscape.com/viewarticle/975440 XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX Very early but Swedish researchers have now identified a molecule that helps stimulate the growth of new insulin-producing cells, and uncovered how it works. These researchers looked at a molecule known as CID661578 and found that it binds to a protein called MNK2. In doing so, i

Big news from Sernova, one of the companies hoping that implantable stem cells will be a functional cure for diabetes. They recently announced that the first person in their trials with type 1 is completely off injected or infused insulin – and is making their own. Stacey talks to Dr. Philip Toleikis, Sernova's president and CEO. He explains how their process differs from some of the other companies looking at stem cells, talks about their partnerships and shares more about the patients doing well in this clinical trial. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News.." got a few minutes? Get caught up! Top stories this week: The Federal Trade Commission probes the prescription drug middleman industry, once a week basal insulin moves forward, DIY insuln dosing systems get a thumbs up at ADA Scientific Sessions, Sernova's stem cell system releases great findings and more! Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry.. requiring the six largest pharmacy benefit managers to provide information and records. They're looking at PBMs such as CVS Caremark; Express Scripts, Inc.; OptumRx, Inc.; Humana Inc and more. The largest PBMs are now vertically integrated with the largest health insurance companies and wholly owned mail order and specialty pharmacies. In these roles, pharmacy benefit managers often have enormous influence on which drugs are prescribed to patients, which pharmacies patients can use, and how much patients ultimately pay at the pharmacy counter. https://www.ftc.gov/news-events/news/press-releases/2022/06/ftc-launches-inquiry-prescription-drug-middlemen-industry?utm_campaign=https://www.ftc.gov/news-&utm_content=1654622484&utm_medium=social&utm_source=twitter XX Confirming what many of you have known for years.. an open-source automated insulin delivery system -- also known as a do-it-yourself system -- was both safe and effective for patients with type 1 diabetes. This is from the CREATE trial, designed to test DIY system, presented for the first time at the ADA Scientific Sessions. This system was made up of the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone, paired with the DANA-i insulin pump and Dexcom G6 continuous glucose monitor. The researchers previously published additional information in the Journal of Diabetes & Metabolic Disorders. https://www.medpagetoday.com/meetingcoverage/ada/99109 XX Stem cell study showing great results. Sernova says the first three patients of six total continue to be insulin independent following treatment. One of the patients has been insulin-free for more than two years, while the other two have been free of the need for medication injections for six months and three months, respectively. At this point, the other three patients in the study have not had the device long enough to determine measurable results. The first three all have A1Cs in a normal, nondiabetic range. Sernova's Cell Pouch is an implantable device that releases the primary donor islets. The device is implanted under the skin in a minimally-invasive procedure. We're talking to Sernova for next week's show; long way to go here but another good result for stem cells. https://www.biospace.com/article/sernova-cell-pouch-device-keeps-type-1-diabetes-patient-insulin-free-for-two-years/ XX Getting closer to once-a-week basal insulin. New study says Novo Nordisk insulin icodec achieved better results than Lantus in some aspects of the study and that overall it was – this is interesting wording – non-inferior. Another previous study showed it also matched well to Tresiba, but that Tresiba caused fewer lows than the once-weekly basal. This study was about type 2 diabetes but insuln icodec is in other trials for people with type 1. https://www.biospace.com/article/novo-nordisk-scores-phase-iii-insulin-win-strengthening-market-position/ XX New partnership between Diabeloop – which makes an automated insulin algorithm - and SOOIL which makes pumps. These are two French companies that have been working together since 2020 but this new announcement was delayed by COVID. They want to bring the product – Diabeloop's DBLG-1 I controller and SOOIL's Dana ACE Pump to the US, Europe and Korea. https://www.drugdeliverybusiness.com/diabeloop-sooil-automated-insulin-diabetes/ XX Civica continues to move ahead with the development of its affordable insulins. They've announced they'll partner with the German company Profil for the clinical trials. Civica plans to set a maximum recommended price to

Dexcom CEO Kevin Sayer joins Stacey from the American Diabetes Association's Scientific Sessions with new G7 information, a response to Abbott's Libre 3 approval, addressing rumors about acquiring another diabetes company and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Got a few minutes? Get caught up on the top diabetes stories and headlines of the past week. The FDA approves Abbott's Freestyle Libre, Dexcom addresses reports it may buy Insulet, Ozempic becomes a TikTok trend, Diabetes Scholarships for college and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, FreeStye Libre 3 gets FDA approval. This is a 14 -day CGM, Abbot says it's smaller and thinner, about the size of two pennies stacked up. Abbott also claims Libre 3 is the most accurate 14-day CGM based on new results. It's worth noting that there isn't another 14-day CGM on the market.. Dexcom is ten days and the upcoming G7 seems to have similar accuracy. However, Libre is less expensive and they say there will be no price increase for this new model. Libre has had iCGM designation since the Libre 2 – but the FDA says it's still not allowed for use with automated insulin delivery systems. I've asked to speak with Abbott and we'll find out more about why that is and what the company plans to do if it can't integrate with insulin pumps in the US. XX Meanwhile, Dexcom pushes back on talk that it was interested in acquiring Insulet. Here's part of the quote: It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change." I'm set to talk to Dexcom's CEO at ADA and I'll definitely ask him about this, even though they say they won't comment further. I do think it's interesting they use the word "merger" and not also "acquisition" – but the stock market seems to believe them. Dexcom went up on the news. XX New information could link environmental pollution to type 1. New study from Norway says even low concentrations of such pollutants can result in cells producing less insulin. New cases in Norway have doubled in children and teens since the 1970s. This study also included samples from American kids. Overall, the researchers found a larger proportion of those with type 1 diabetes these pollutants in their blood. They also found when mice were exposed to the pollutants, insulin production went down. https://www.news-medical.net/news/20220530/Environmental-pollutants-may-be-the-reason-behind-development-of-type-1-diabetes.aspx XX Whey protein may be the next big thing for people with type 2. Drinking a pre-made shot before meals with a low dose of whey protein seems to help better control blood glucose levels. In this study, people went about their daily lives with no changes but the whey drink. Then they spent a week with no whey, all while wearing a CGM. On average, people had two hours additional per day of normal blood sugar levels compared to the week they skipped the protein drink. The researchers believe the whey slows down food in the digestive system and also stimulate hormones than help keep glucose from rising. This was a small study, but you can bet you'll be hearing a lot more follow up.. it's a simple and promising treatment. https://scitechdaily.com/just-a-small-amount-of-protein-supplement-helps-control-type-2-diabetes/ XX At least at one hospital, the pandemic showed the telemedicine and CGM use can make a big difference in kids with type 1. For the study published in BMC Pediatrics, these researchers used data from Children's Medical Center Dallas . While the number of office visits among patients decreased during the pandemic, there was no effect on disease management in this group – both glucose control and hospitalization rates were unchanged. However, the results highlighted existing disparities among patients in minority and low-income demographics. Both before and during the pandemic, Black and Hispanic patients and those without commercial insurance had worse glucose control and hi

Diabetes camp is great, but what if there were a program to take teens with type 1 on a more adventurous journey? A new, international travel program to foster confidence and independence is in the works. Savannah Johnson is the founder of Type 1 Way Ticket. Diagnosed as a toddler, she says travel as an adult changed her life. We'll find out more about this new adventure travel program, what parents and teens can expect. More about Type 1 Way Ticket Go Fund Me Page here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! Got a few minutes? Get caught up! Top stories this week: Dexcom is reportedly in talks to buy Omnipod, Abbott & Dexcom sue and countersue each other over patents, new study showing people with type 1 diabetes are living longer, a JDRF advocate climbs Mt Everest, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story this week is still developing.. but Bloomberg reports that Dexcom is in talks to acquire Insulet, the makers of Omnipod. Neither company has commented publicly on the report. Bloombeg says, "Talks between the companies are ongoing and an agreement could be reached in the coming weeks, said the people, who asked not to be identified because the information is private. Discussions could still be delayed or fall apart, the people said." Insulet's stock has gone up and Dexcom's has gone down. These companies already have an agreement in which the Omnipod and Dexcom CGMs communicate.. Dexcom also has an agreement with Tandem and some other companies – those aren't expected to change in the short term, but there are a lot more questions than answers about this report. I'm scheduled to talk to Dexcom's CEO in early June and we'll continue to follow this story. https://www.bloomberg.com/news/articles/2022-05-23/dexcom-is-said-in-talks-to-acquire-device-firm-insulet XX Meanwhile, Dexcom and Abbott are currently going head-to-head over twelve separate patents covering their respective CGMs. Both companies are launching newer products soon, with the Dexcom G7 and Freestyle Libre 3 already available in Germany. Dexcom first sued in 2021.. Abbot then countersued. A UK High Court will hold three separate technical trials, planned for December 2022, April 2023 and July 2023. https://www.juve-patent.com/news-and-stories/cases/dexcom-and-abbotts-fight-over-glucose-monitoring-patents-intensifies-in-europe/ XX People with type 1 diabetes are living longer according to a new study based on data from Australia, Denmark, Latvia, Scotland, Spain, and the United States. The years analyzed varied by country, but overall, they cover 2000 to 2016 and include 1.5 million person-years. The data show that country-by-country annual changes in age- and sex-standardized all-cause mortality among people with T1D dropped by between 2% and nearly 6% over the study period. The risk of dying was still higher than in people without type 1, mostly because of diabetes complications. https://www.ajmc.com/view/all-cause-mortality-falling-among-people-with-type-1-diabetes XX A new study finds that herpes virus may contribute increased risk of type 2 diabetes. Herpes viruses are one of the most common viruses in humans, with 8 types currently known. Any of these can cause lifelong latent infections after an initial, usually mild or asymptomatic primary infection. Until recently, viruses had only been proposed as a potential trigger for the development of type 1 diabetes. This study was based on health data from nearly 2000 people, men and women, in Germany. The researchers found that herpes viruses consistently and complementarily contributed to the development of prediabetes and diabetes, even after accounting for sex, age, BMI, education, smoking, physical activity, parental diabetes, hypertension, lipid levels, insulin resistance, and fasting glucose. https://www.pharmacytimes.com/view/study-herpesvirus-infection-may-increase-risk-of-diabetes XX This one sounds kind of odd, but a one-time diabetes treatment may lower average blood sugar and improve long-term insulin resistance and pancreatic function. The company is Fractyl, the treamtment is an outpatient proceure that applies heat to the intestinal walls to – quote – strip out and reset the mucosal lining, which can thicken over years from dietary fats, sugars and other foods. Fractyl believes this thickening contributes to the insulin resistance seen in Type 2 diabetes. The device has breakthrough FDA designation, but no approval yet. It is approved in Europe. https://www.fiercebiotech.com/medtech/fractyl-shows-its-intestine-resurfacing-device-

Mike Joyce is out there – somewhere – on the Pacific Crest Trail. He set out a couple of days before this episode airs, on a 2600 mile long distance hike. It's part of his attempt to complete what's called the Triple Crown of Hiking. He's already done the Appalachian Trail and the Continental Divide trail. Only 535 people have completed the Triple Crown. Mike lives with type 1 and he'll share how he went from pretty sedentary to long distance hiker and how he manages his diabetes on these incredibly long and challenging hikes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Follow Mike on Instagram Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! Got a few minutes? Get caught up! Top stories this week: new research that keeps beta cells safer after transplant, a new drug for type 2 also shows weight loss success, the makers of Afrezza buy a simple patch pump, Beyond Type 1 tackles mental health and diabetes and lots more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, another approach to beta cell encapsulation. There are a few methods being tested to protect the transplanted cells from the body's immune system. A new and promising one seems to be a new biomaterial in the form of microgel beads. This study was in mice only but after three months the beta cells survived and maintained blood sugar levels with no rejection drugs. Interestingly, this study put the cells into the omentum, not the liver as is apparently the usual spot. I never heard of the omentum.. in case you haven't, it's a layer of tissue connecting the stomach with the other abdominal organs. It's non-vital so it's safer if any complications take place. No word on when human trials might begin here. https://newatlas.com/medical/microgel-beads-safer-path-cell-transplants-treat-diabetes/ XX FDA approval for a new injection for type 2 diabetes called Mounjaro. It's made by Eli Illy and is shown to lower blood sugar and can help patients lose weight. Existing medicines target a hormone called the glucagon-like peptide-1 that is involved in the control of blood sugar. But Mounjaro targets a second hormone, the glucose-dependent insulinotropic polypeptide, as well. It is the first medicine to target both. While not yet approved as an obesity treatment, it's performed very well in clinical trials for weight loss. One study showed it helped patients lose an average of 16 to 22 percent of their weight: That's on par with bariatric surgery https://www.statnews.com/2022/05/13/fda-approves-lilly-diabetes-drug-that-analysts-expect-to-be-a-big-seller/ XX Big deal for MannKind, the makers of Afrezza inhalable insulin. They're acquiring Zealand Pharma's wearable V-Go Insulin Delivery Device. The V-Go is a patch pump that's meant for people with type 2 – it delivers basal insulin at a set rate all day long and can give boluses only in increments of 2 units of insulin at a time, up to 36 units in 24 hours. The deal is expected to close by the end of the month. https://www.mddionline.com/diabetes/mannkind-acquires-wearable-insulin-device-zealand-pharma XX Young adults who were at risk of food insecurity had an increased incidence of diabetes 10 years later, according to the results of a study from Washington State University. Although previous research has associated food insecurity with a range of health issues, this study showed a connection over time, which could indicate a causal relationship. The investigators could not identify the exact reason for this connection, previous research has shown that food-insecure households often have diets with lower nutritional values. The study results did not indicate differences among ethnicities or races, but they also said that a limitation of the study was the number of minorities in the sample, which could be too low to show a pattern, according to investigators. The investigators plan to evaluate food insecurity risk and health issues within American Indian and Alaska Native and American Indian populations, which they said are often left out of annual reports on food insecurity. XX Beyond Type 1 has a new mental health portal.. announced as part of this Mental Health Awareness Month. The global nonprofit is partnering with BetterHelp to provide affordable mental health resources and services to its online community with two weeks of free, professional online therapy. Beyond Type 1 will continue to expand the resources available on the site.. it's not just for this month. https://beyondtype1.org/mental-health/. XX Another entry into the quest to find a non-invasive way to monitor glucose. Movano Inc reports they have – quote - successfully validated the functionality of its proprietary and patented system-on-a-chip. T

We've got an update from Beta Bionics, makers of the iLet pump. This is the system that, among many other things, requires very little input from the user. They're hoping this makes it accessible for more people. Stacey talks to to interim CEO Martha Goldberg Aronson. She shares more information about recent studies regarding the Ilet, news about their submission to the FDA and a look into the future for this long-awaited piece of technology. More about Beta Bionics This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Top stories this week: racial disparities in treatment for kids with type 1, new study looks at oral insulin for type 2, nanoparticles tested to prevent diabetes and why is there a Squishmallow toy being marketed as having T1D? That and a lot more. Full transcript and links to sources below. Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, Black children with type 1 diabetes experience disparities in health outcomes compared with other racial and ethnic groups with similar neighborhood opportunity profiles. That's according to a study published in the Journal of the American Medical Association Network Open. This was a very big study – more than 70-thousand patient encounters under the age of 21 from 2009 to 2018. They looked at something called the Child Opportunity Index. This It combines data from neighborhood-level indicators, like good schools, parks and playgrounds, clear air and safe housing. They found that the probability of readmission within a year was significantly higher among Black children with a very low COI category versus Hispanic children and White children at the same COI category. These researchers say doctors and educators need to be aware and include interventions that target racial disparities. https://www.physiciansweekly.com/outcomes-worse-for-children-with-type-1-diabetes-who-are-black XX New research suggests the people of certain racial ethnic groups should be screened for diabetes at lower body mass index than white people. A recommendation that contradicts recent guidelines from the United States Preventive Services Task Force. At a time when a lot of medicine is trying to rid itself of race-based tools this could be tricky.. but these researchers say that using a one-size-fits-all approach to screening, when diabetes is two to four times more prevalent and more deadly in Black, Hispanic, and Asian Americans, is likely to result in underdiagnosis of the disease, and widen health gaps. https://www.statnews.com/2022/05/09/race-ethnicity-bmi-diabetes-screening/ XX New partnership between JDRF, Yale University and a company called NexImmune. That company has something called Artificial Immune Modulation nanoparticles and the idea here is to if that could work with Teplizumab to delay or prevent type 1. Teplizumab is already being tested as a prevention method and is back in front of the FDA. NexImmune says it's wider plan is to use the body's own T-cells to generate a specific immune response to prevent not just diabetes but other auto immune conditions and even cancer. https://www.jdrf.org/press-releases/neximmune-yale-and-jdrf-enter-into-600k-research-partnership-for-type-1-diabetes/ XX Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the world's first Phase 3 study of oral insulin This is being looked at just for type 2 right now. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control, with a secondary endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. They hope to announce results in January of 2023. https://www.biopharma-reporter.com/Article/2022/05/05/Oramed-hits-oral-insulin-clinical-trial-milestone XX New partnership between two diabetes heavy weights. The Diabetes Research Institute, DRI Foundation Canada (DRIFCAN) and Alberta Diabetes Institute (ADI) have announced a research partnership The CEO of DRI says "Type 1 diabetes knows no borders or boundaries; nor should the research to find a cure. There's a lot of research funded by these groups, included islet and stem cell transplantation. https://finance.yahoo.com/news/diabetes-research-institute-foundation-joins-193300513.html XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time,

Dexcom's G7 is in front of the FDA right now. There are some significant changes to the system, including what's basically a snooze for essential alarms, including the urgent low. Dexcom's Chief Technology Officer Jake Leach answers your questions about adhesive, direct to watch, accuracy, and even mentions the G8. Here's more information about the European approval (includes a video of the system) This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News..." Got a few minutes? Get caught up! Top stories this week: An FDA hiccup for Vertex, Omnipod 5 starts wider rollout, New peek at Dexcom G7 features, Beta Bionic study info, "Hey Alexa, predict my blood sugar" and Healthline shuts down their main source of diabetes news and information. -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story – bit of a surprise for Vertex – the FDA puts a clinical hold on their newest trial. This is the company that made big headlines last fall – that New York Times article likely sent to you by everyone you know about a stem cell cure for type 1. That's when Vertex reported data on the cell therapy from a single patient who achieved a "robust" restoration of islet cell function after receiving a drug called VX-880. That response is going strong they say at day 270. This week, Vertex showcased results from another patient and said a third patient has received the full dose. A company spokesman says they're surprised by the clinical hold given the evidence so far and there have been no serious adverse events. They say they'll work with the FDA to get the trial moving again as soon as possible. https://www.fiercebiotech.com/biotech/unwelcome-surprise-vertex-fda-slaps-hold-phase-12-diabetes-cell-therapy-study XX Insulet announces that Omnipod 5 has completed the Limited Market Release and will be rolling out to a wider audience soon. Those who signed up for what they call the interest list will be notified first – we're told watch for that email this week. If you haven't signed up, sit tight. Omnipod 5 still isn't yet available through all insurers and at every pharmacy, but the roll out will continue slowly through the year. https://www.omnipod.com/current-podders/resources/omnipod-5/faqs?fbclid=IwAR1fghbXl4uP4H3z8DGovriAocpZyDyPzLdPzME_taonv3_ZfPC3XqukHJY XX We're learning more about Dexcom's G7 – approved in Europe and in front of the US FDA right now. Sensors will have a bit of a grace period – they'll keep working 12 hours after the 10 days are up. You'll also be able to silence the urgent low and sensor fail alarms for six hours – that's new. I'm talking to CTO Jake Leach for next week's long-format show and he's got a lot of info to share. I asked as many of your questions as I could, so please come back for that one. XX New study results about the iLet, the insulin only bionic pancreas from Beta Bionics. This is one of the many studies presented at A-T-T-D.. People in the study saw about half a point come off their A1Cs after 13 weeks and there was no increase in hypoglycemia. They also saw more than 2 and a half hours more time in range. The iLet is unique in that you only enter your weight and tell the pump system when you're eating – there are no basal rates or a need to enter carbs. No timeline for release but the company says its regulatory submission is currently under FDA review. https://www.globenewswire.com/news-release/2022/04/30/2433019/0/en/The-iLet-Bionic-Pancreas-Significantly-Reduced-HbA1c-and-Improved-Time-in-Range-vs-Standard-of-Care-for-a-Diverse-Range-of-People-with-Type-1-Diabetes.html XX Amazon.com's online pharmacy PillPack has agreed to pay almost 6-million dollars to resolve claims that it overcharged government health insurance programs by dispensing more insulin injector pens than patients needed. That's the headline, but -editorial here – this story just shows a lot about what's wrong with our system. Many of us have had this happen – used to be if you had a prescription for insulin pens, they'd just give you the box of 5 – even if the prescription was written for 3 or 4. Now, they have to break open the box and count out the exact amount. It's not as though a patient was over-charged.. and that's not the focus of this lawsuit. This was about government health insurance programs. I get it, we're all paying for that in our taxes, but there's got to be a better way. Maybe pass that co-pay cap, or let Medicare negotiate prices or just cap the price overall. Then this issu

This week, we're having a conversation about diabetes beyond numbers. Yes, there are a lot of those and they are very important. But have you ever stopped to think about the mental energy and emotional effort behind those numbers? Even if your A1C and Time in Range are what your doctor wants to see. Our guests, Allison Nimlos and Sara Adams are therapists who both live with diabetes. They've come together to host a conference all about mental health and diabetes. Stacey asks them about a lot of very common issues and about how to start those conversations. The conference takes place May 20-21. It's virtual - click here for more info. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include headlines from the ATTD Conference - that's the Advanced Technologies and Treatments for Diabetes Conference. There's a bit of new information about the Dexcom G7, Beta Bionics announces it will release pivotal trial results, and news of the first AID system using the Libre 3 is announced. Along with ATTD there's news about type 2 diabetes and grocery stores, all types of diabetes and nursing homes and a person with T1D is on the cover of British Vogue. Learn more about T1D Exchange here Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX This week ATTD begins – that's the Advanced Technologies and Treatments for Diabetes Conference, so you can expect to hear a lot of news. I'll include some here, some next week and we've got future interviews lined up with a lot of the companies making headlines.. XX First up, a peek at more features in Dexcom's G7 system. It's approved in Europe but not the US and features what they're calling more meaningful alarms. You can silence more alarms, including urgent low & sensor fail for up to six hours, there's also a new 12 hour grace period at the end of the 10-day sensor life. It's already been announced the G7 has a much shorter warm up period, only half an hour, and is much smaller. -- Also at ATTD, Beta Bionics will be releasing Pivotal Trial Results of the iLet Bionic Pancreas. The iLet is a pump – connected to a CGM that is designed to autonomously determine and deliver insulin doses to control blood glucose levels. You'll recall this pump was originally designed to deliver both insulin and glucagon.. but the current iteration is insulin only. They says this pivotal trial population was more diverse and representative of the United States type 1 diabetes community than any previous pivotal trial of an automated insulin delivery system. We'll have more info on what these trials actually said next week. https://www.globenewswire.com/news-release/2022/04/25/2427846/0/en/Pivotal-Trial-Results-of-the-iLet-Bionic-Pancreas-To-Be-Presented-at-ATTD.html XX The first automated insulin delivery system using the FreeStyle Libre has been announced. This is in Europe and it's the Libre 3, Ypsomed pump and CamDiab software system. Expected by the end of the year, this is described as a self-learning app, a hybrid, closed-loop system that runs on an Android smartphone and can be tuned to users as young as one year old https://www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe XX And a new consensus meeting on Time in Range. In 2019, diaTribe formed the Time in Range Coalition, whose goal was to ensure that Time in Range (TIR) becomes the primary glucose metric for daily management, complemented by A1C, in diabetes care globally. But there isn't an internationally consensus on the use of CGMs in clinical trials. This meeting will help standardize those methods. XX Other highly anticipated – or at least well-publicized- studies coming to ATTD include those from Tandem and Omnipod and almost every big diabetes tech company. Lots more to come next week and we already have interviews set with Dexcom and Beta Bionics to we'll talk about all this in the long format episodes in weeks to come. XX Overtreating type 2 diabetes is apparently very common in nursing homes.. which can be a big problem as people get older and may require changes. New study in the Journal of the American Geriatric Society show about 40% of nursing home residents with type 2 diabetes may be overtreated. These researchers say one big issue is that at admission, residents are given a very big medical work up, but that isn't followed up on year to year. Often as people age, its recommended their A1C is maintained a bit higher, for safety reasons, so a target A1C could easily change years or even months after someone moves into assisted care or a nursing home. https://www.healio.com/news/endocrinology/20220422/diabetes-overtreat

Could this finally be a big shake up in the price of insulin? Civica Rx plans to sell the most popular types of fast and long acting insulin for a flat price of 30-dollars a vial. This week you'll hear from Ned McCoy, Civica's Chief Operating Officer. He explains why they're confident this will work, who will be able to buy the finished product, when it will be available and what Civica RX is all about. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include a new company called Luna Diabetes founded by some heavy-hitters in our community, a new #T1D telehealth study for underserved kids, improved life expectancy for people with type 2 and a look at 420 with diabetes. Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story is a very interesting LinkedIn post about a new company and product.. Luna Diabetes aims to fill in a big gap – overnight automated control for people who use smart insulin pens. They're calling it A-I – automated injections, a way to combine the convenience of insulin pens with the clinical outcomes of automated insulin delivery – like Control IQ or Looping. Some heavy hitters here – the founders are John Show-lund Sjolund – founder of Timesulin, John Brilliant a co-founder of BigFoot biomedical and Sean Saint, founder of Companion Medical who made the InPen automated pen system. The release shows a little device but no real information yet. Is it an automated basal delivery system for overnights only? pivotal trial to start by the end of this year We'll keep you posted.. https://www.lunadiabetes.com/ XX A look at pediatrics in under-served communities shows most children are not meeting A1C goals. A new grant from the Helmsley Charitiable Trust will focus on expanding access through remote care. Many providers lack the money to set remote care up and use it effectively – telehealth systems and things like that. A large pediatric endo group in Buffalo, NY will work with Cecelia Health, a virtual first health care provider. They'll work with about a thousand patients to explore how improving access to remote support and the internet to better manage chronic conditions will improve outcomes. This is along with existing diabetes technology like pumps and CGMs. https://www.benzinga.com/pressreleases/22/04/n26682238/improving-outcomes-for-children-and-adolescents-living-with-type-1-diabetes-is-the-goal-of-a-colla XX Big news for people with diabetes in Australia. The government has committed to subsidized access to continuous glucose monitoring and flash glucose monitoring technology for all people living with type 1 diabetes. Right now, people under 21 are already eligible as as women who are actively planning a pregnancy or are pregnancy. This agreement will make everyone eligible for just over 30-dollars a month. Right now it costs over 300-dollars a month. I'm going to link up info from the incredible Diabetes Australia advocate Renza Scibilia who's been on the show before and who's been working on this for more than ten years. Congrats Renza and all who will benefit. https://www.diabetesaustralia.com.au/mediarelease/diabetes-australia-welcomes-bipartisan-commitment-to-cgmforall/ https://diabetogenic.blog/2022/04/17/oh-happy-day/ XX Not a big surprise but important information about improving life expectancy in people with type 2. New study shows reducing A1C, blood pressure, cholesterol and BMI makes a big difference. This was a University of Florida Gainesville study.. biggest improvement in all of these was reducing A1C from the highest in the study – about 9.9 - to the lowest about - 7.7 - added almost 4 years of life expectancy. These researchers say it's very motivating to patients and clinicians to see these gains and it may help them choose treatment goals. https://medicalxpress.com/news/2022-04-treatment-goals-diabetes-life.html XX We've talked about One Drop before.. more than a meter, they now call themselves a digital coaching company. And a new evaluation from an independent, third-party found that One Drop's support program effectively improves the health of people living with prediabetes, diabetes, and high blood pressure. The program could also cut down on annual healthcare costs. This is from the independent Validation Institute, dedicated to providing unbiased, data-driven insights on hea

We don't need to tell you that the mental burden of diabetes is a heavy one. And most of us – caregivers and people with diabetes alike - are never given any resources to help. My guest this week is trying to help. Dr. Mark Heyman is a diabetes psychologist and lives with type 1 himself. His new book is called "Diabetes Sucks, and You Can Handle It." We talk about why he wanted to write the book, who it's for and what we can learn from his experiences. talk about some of the common fears and worries he hears and what he advises his patients. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

Sage Donnelly started kayaking with her father at age two, when he'd sit her in the boat next to him. She was diagnosed with type 1 diabetes at age 3 and got right back in the water. After watching competitions for several more years, at age seven she told her parents she wanted to compete. She wasn't kiddng! Donnelly was the Jr. Women's Freestyle World Championship and earned a spot in the Olympics. More recently, she's decided to go in another direction and shares what prompted the change. We talk about how she keeps her diabetes gear protected in the water, treating lows during 3-day remote adventures and more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. ----music----- Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include testing a new treatment for leukemia to see if it might help with type 1, Black patients with type 1 are at higher risk of DKA, transitioning from teen care to adult care, updates on Eversense in the US and Dexcom One in the UK and front office changes at Beyond Type 1 and Vertex. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Interesting look at whether a treatment for leukemia might work against type 1. Very early on here.. but AVM Biotechnology has received a grant to find out. The drug doesn't have a name yet.. it's referred to as AVM-0703 and has been shown to delay T1D in the lab. A preclinical dose-finding and mechanism of action (MOA) study in three scenarios including pre-diabetic, new-onset, and established diabetes is the first aim of the program. Those results will be used to determine the targeted dose to be used in a pivotal efficacy study for reversal of new-onset and established diabetes. It is anticipated that for patients not showing remission, AVM0703 may reinforce other immunotherapies allowing a wider range of patients to achieve insulin independence. https://www.businesswire.com/news/home/20220405005529/en/AVM-Biotechnology-Awarded-1.6-Million-Phase-II-SBIR-Grant-to-Study-AVM0703%E2%80%99s-Potential-to-Reverse-Type-1-Diabetes XX Black patients with type 1 faced a significantly higher frequency of diabetic ketoacidosis during the pandemic, and particularly during surges, researchers reported. This was a big study at several different health centers and hospitals. Researchers found there was not significant difference in the number of patients in DKA from 2019 versus 2020.. but there was a higher proportion of Black patients. The trend continued through the pandemic and again, it was significant, 48-percent versus 18 percent. Pandemic surges emphasized the disparity even more. These researchers say their work shows racial inequities in diabetes care were present before the pandemic, starkly visible during the pandemic, and will continue to persist after the pandemic -- unless we systemically root out and target racial inequities in diabetes care," https://www.medpagetoday.com/endocrinology/type1diabetes/98044 XX A new look the transition from pediatric to adult care for people with type 1 shows.. it needs improvement. This research – based on interviews with older adolescents showed many felt unprepared and dissatisfied with the transition process. Three big takeaways – the teens are aware of the changing relationship with their parents and health care teams and often want more independence than the parents are willing to give… the teens want acknowledgement that being diagnosed at different ages means they may be more or less comfortable with self-management and the third is that they think their pediatric team isn't preparing them to work with adult providers. Personally, this means a lot to me – as my son is 17 – and I'll be asking his peds endo to work with him more on this stuff in the next couple of years. https://www.healio.com/news/endocrinology/20220401/novel-programs-needed-to-improve-transition-from-pediatric-to-adult-diabetes-care XX DiabetesWise announces the launch of it's new Pro website. It's an unbranded non-biased resource created at Stanford University to help make providers more informed about diabetes devices and streamline the prescription process. We've talked about Diabetes Wise before and I'll link it up here. It's easy to feel overwhelmed by the evolving choices and providers are in the same situation. The DiabetesWise Pro website has an extensive Device Library where providers can learn about all of the FDA-approved diabetes devices on the market based on the patient's considerations. The user can compare the devices from the different manufacturers using the Compare Device tool, which displays a side-by-side analysis of the components and details of each technology, including the steps for ordering and prescri

It's always a privilege to talk to one of the Joslin Medalists. This week you'll hear from Laurie Harper. She was diagnosed as a toddler in 1955 and will mark 67 years with type 1 later this year. She shares what she remembers about her early years with diabetes, how her family adjusted, the technology she started with and what she uses now. The Joslin Medalist program recognizes and studies people who've lived with type 1 for at least 50 years. Laurie tells us more about the medalist program, about aging with diabetes and she takes a look back at how different the management was almost 70 years ago. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about the Joslin Medalist Program Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include new information about the temperature at which insulin can be safely stored, a warning about men taking Metformin, news about sexual health and women with diabetes, and a heads up about a virtual mental health conference coming up for people with diabetes. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story.. a look at how insulin holds up under real-world and often hotter conditions than is recommended. Doctors without Borders found that a range of insulins can be stored at warmer temperatures than previously recommended. They showed it's okay above 77-degrees all the way up to 99 degrees for four weeks. This is really important not just for emergency settings like refugee camps but for people who live in areas without refrigeration. They often have to travel to health clinics which may be far away and which can't send them home with the insulin. The group now says pharmaceutical corporations should urgently submit to regulatory authorities for use of insulin under expanded temperature ranges. This came out a few weeks back, but I haven't seen it anywhere. https://www.doctorswithoutborders.org/latest/msf-study-shows-some-insulin-can-be-stored-warmer-temperatures XX Big headlines this week about Metformin and the risk of of birth defects in the babies of men who take it. Metformin is a very common diabetes drug, taken by tens of millions of people around the world. Sons born to men taking it were more than three times as likely to have a genital birth defect as unexposed babies. These problems were relatively rare, occurring in fewer than 1-percent of all babies with dads who took Metformin but it's significant because tens of millions of people worldwide take metformin. These researchers say the paper's findings are preliminary and observational only.. and that men with diabetes should NOT abruptly stop metformin before trying to conceive. Reassuringly, the researches saw no effect for men who took the drug earlier in life or even a year before. Expect a lot more research to come on this one. https://www.science.org/content/article/rare-genital-defects-seen-sons-men-taking-major-diabetes-drug XX Grain of salt needed here, but new research may show that people with type 1 are more likely to manage better if they have high levels of psychological resilience. This was a British study that followed 18-hundred people with type 1 or type 2 diabetes. They used a questionnaire to determine how they adapted to change and focused under pressure. The researchers found that people with type 1 diabetes who had low psychological resilience also had poorer blood sugar control after two years. The idea is that something like this would offer the opportunity to identify those who might benefit most from additional support when they are first diagnosed. https://medicalxpress.com/news/2022-03-psychological-resilience-future-high-blood.html XX Among patients with diabetes, women are just as likely as men to suffer from sexual dysfunction, but their issues are overlooked. Big session on this at the Diabetes UK Professional Conference this week. Reserachers say women with diabetes can experience reduced sexual desire, painful sex, and other issues which can increase the risk of depression. But these issues are usually untreated despite help being available. They talked about the embarrassment factor and the idea that many women with sexual dysfunction don't realize diabetes could be a factor. They encourage health care professionals to go beyond conversations about contraception, pregnancy and menstruation. A recent study led by Belgian researchers found that among more than 750 adults with diabetes 36% of men and 33% of women reported sexual dysfunction. https://www.medscape.com/viewarticle/971208 XX Concerning new trend about pre-diabetes.. it's doubled among children over the last 20 years. The increase was seen over almost all subpopulations of young Americans, reg

There's a new plan to manufacture and sell insulin at a much lower list price. The company behind it is non-profit Civica RX, which has support from JDRF. Stacey talks to JDRF CEO Aaron Kowalski about what their role is here, how realistic this plan is, who it may help and a lot more. They also spend some time talking about the reorganization of JDRF and what the future after COVID 19 looks like for them. More about Civica's Plan (we'll talk to them in a future episode) Here's the episode Stacey references with Thom Scher and Aaron Kowalski This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News..." Got a few minutes? Get caught up! Our top stories this week include increased risk of type 2 after having COVID-19, CGM gets high marks as a telehealth device, Ypsomed pump picks a new partner, more study on the TB vaccine for type 1 and T1D: The Movie update! -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX People who recover from a mild case of COVID-19 appear to have an increased risk for subsequent new-onset type 2 diabetes… but not other types of diabetes. This is from a big new study in Germany. It lines up with previous studies of more seriously ill patients with COVID 19 who had increased rates of type 2 in the months following. This was more than 35-thousand patients – no prior history of diabetes. The risk of developing type 2 increased by 28-percent if the person had COVID, again even a mild case. The researchers say anyone who tested positive for COVID should be aware and get screened for diabetes in the months and years following. https://www.medscape.com/viewarticle/970600 XX Big new study that – interestingly – talks about the CGM as a telehealth device. It looked at how doctors continued to care for children with type 1 before and after the first year of the COVID pandemic. The use of CGMs increased significantly among those with non-commercial insurance… from 24 percent in 2019 to 35 percent by the end of 2020. Another finding in this same study.. those with higher A1Cs, racial minorities, and those with non-commercial insurance were more likely to have high rates of DKA. But the implementation of telehealth and CGMs increased parental oversight which resulted in better care at home and lower than expected hospitalization rates. I want to dig a little deeper here because a lower hospitalization rate during the first year of the COVID pandemic overall.. was found to be tied to a lot of fear about going to a hospital during that time. https://mhealthintelligence.com/news/telehealth-helped-maintain-type-1-diabetes-care-among-kids-during-pandemic XX Swiss pump maker Ypsomed announces the software they'll use for their automated insulin delivery. Ypsomed will partner with CamDiab's CamAPS app. The launch will start in select major countries in Europe, with other territories to follow over the course of 2022. This includes a hybrid closed loop – like Omnipod 5 and Control IQ - as well as smartphone control.. it's compatible with Dexcom's G6. It'll start on Android then roll out on iOS.. Ypsomed is partnering with Lilly to come to the US – we've had them on the show before talking about this. They hope to submit to the FDA this year. https://www.drugdeliverybusiness.com/ypsomed-partners-with-camdiab-on-smartphone-based-automated-insulin-delivery/ XX The FDA is due to make a decision on Teplizumab by August 17th. This is a drug that has been shown to delay type 1 diabetes. Last year the FDA turned down Provention Bio, asking for a resubmission with more information. The company is also running the phase 3 PROTECT trial of teplizumab. That's in newly-diagnosed type 1 diabetes patients. They hope to expanding the indications for the drug. https://pharmaphorum.com/news/fda-sets-august-decision-date-for-proventions-type-1-diabetes-drug/ XX More study underway into the tuberculosis vaccine as a treatment for type 1. This is Dr. Denise Faustman's lab – they're recruiting 150 teen with type 1 for pediatric clinical trials of the shots. Faustman's work is controversial because her studies have been very small and many experts say they don't show significant improvement. But Faustman says the vaccine appears to help patients with Type 1 diabetes by altering their immune system and that even though no one in her trials is off of insulin, there is improvement. https://www.bostonglobe.com/2022/03/21/metro/could-100-year-old-vaccine-treat-type-1-diabetes-mgh-researchers-are-working-find-out/ XX If you're watching live, today is the last day to back the Kickstarter for Type 1 The Movi

There's been a lot of excitement recently about stem cell transplants and progress toward using this as a functional cure for type 1. There are a few separate groups working on this, this week we're talking to ViaCyte to get past the hype and look at the real progress here. You'll hear from ViaCyte's Head of Clinical Development Dr. Manasi Jaiman. ViaCyte has been studying stem cell transplants for several years – and recently started working with the gene editing technology CRISPR. We're going to talk about what this is all about, how close they really are, and who would even be in line to benefit. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Top stories this week: Dexcom G7 approved in Europe, JDRF speaks out on non-profit insulin plan, Ukraine diabetes aid progress, texting for T2D, Reaction to Pixar's Turning Red -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story this week.. Dexcom gets the CE Mark for it's new G7 system, which means it's approved in Europe. The approval is for people ages 2 and up, including pregnant women. I'm putting the full screen photo up here and I'll post this on the website and in the FB group for those listening.. interesting to finally get a good look at the much smaller applicator – as expected looks a lot like the Libre. Also interesting, all the PR for this has said, developed in partnership with Verily.. remember them? That was part of google, probably best known for saying they were going to develop a contact lens that would monitor glucose. I've reached out to Verily, love to know more about this partnership. Anyway, we've done a ton on G7, I'll link up some of our recent conversations with the folks at Dexcom. They submitted to the US FDA at the end of 2021, no firm timeline on US approval. https://www.medicaldevice-network.com/news/dexcom-ce-mark-g7-cgm-system/ XX Some good news about living longer with chronic conditions, including diabetes. This was a 20-year British study that ended in 2011, so one caveat here, it doesn't include COVID. Men gained 4-point-6 years of life expectancy; women gained 2-point-1. When it comes to disability-free life expectancy, men gained about a year less and women stayed the same. This included people with chronic conditions including those with diabetes. These researchers do point out that while they'd expect to see the same increase in the US – the lack of health and social safety net programs could make a negative difference here. But they point to CGM technology and better medication as making a big difference for those with diabetes. https://www.healthline.com/health-news/why-people-with-chronic-conditions-such-as-diabetes-are-living-longer-without-disability#Cognitive-impairment-is-the-exception XX Children who develop type 1 diabetes show epi-genetic changes in the cells of their immune system long before the antibodies of the disease are detected in their blood. An epigenetic change affects how our genes work. Outside factors such as environmental, viral infections, are usually the cause. These researchers say these are previously unknown changes that signal the increased risk of developing type 1 and could give an even earlier indication than the anti-body marker tests available now. https://www.news-medical.net/news/20220316/Epigenetic-changes-could-be-a-biomarker-for-early-detection-of-type-1-diabetes.aspx XX Could text-messaging with their doctors help people with type 2? A new team in Chicago is looking at text-based intervention in underserved communities. The intervention will deliver personalized information directly to patients through text messages, including reminders about self-monitoring and prescription refills, interactive office hours and general information about diabetes, motivational support and answers to frequently asked questions. These doctors say the idea is to create more opportunities for patients to meaningfully engage and reduce barriers by employing technology already in people's hands. https://today.uic.edu/an-sms-solution-for-type-2-diabetes XX Last week we told you about the effort by Civica RX to make affordable insulin. Civica, is a nonprofit generic pharmaceutical company. JDRF directed funds to this effort and CEO Aaron Kowalski wrote an op ed that I'll link up. In it, he talks about the success Civica has had lowering the costs of other medications. We'll have Kowalski on the show soon and I've reached out to Civica as well. This would lower the price to $35 a vial no matter your insurance. Congress still hung on a $35 co-pay cap for those with insurance. http

What happens when the diabetes community and the Star Trek fandom collide? The actor who brought these groups together spent time as a blue-skinned alien on Star Trek Discovery. Now Noah Averbach-Katz wants to make a movie where T1D is front and center. He shares more about the Kickstarter campaign to fund it, and about his time in the Star Trek world This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Stacey Simms 0:00 Diabetes Connections is brought to you by Omnipod take Omnipod dash out for a spin with a no commitment free 30 Day Trial, by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week when the diabetes community and the Star Trek fandom collide! The actor who brought these groups together spent time as a blue skinned alien with a lot of prosthetics on Star Trek Discovery, but he had to find a way to reach his fingers for blood sugar checks. Noah Averbach-Katz 0:45 I sort of explained that to him. And they said, Well, it's fine. We'll just put you in gloves the whole time. So the entire time of my sort of run of the show, I am wearing like black leather gloves. Regardless of what I'm doing. I'm eating breakfast, I'm wearing black leather gloves, I'm flying a spaceship, I'm I'm wearing black leather gloves. And that was just so I can have easy access to my fingers. So I could test. Stacey Simms 1:10 That's Noah Averbach-Katz . And while we talk a lot about Star Trek, he's really here to share the news about a movie he's making called type one. We've got all the info about the Kickstarter campaign to fund it, and other ways you can help. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Always so glad to have you along. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. I didn't plan it this way. But it's interesting. This is the second week in a row that we're doing more of a pop culture or media type episode about diabetes. Right? We talked about turning red last week, if you missed that episode, that is the new Pixar movie on Disney plus, that features two characters with diabetes in the background. And I talked to Susan Fogg from Pixar, who made that happen with her whole team, of course, and one of the things that Susan talked about was why it was just fine to have diabetes in the background, right? That's about what isn't her life. That's how it is for many people with diabetes. It's not always front and center. It's not always what you want to talk about. But this week's guest looked at things a little differently. And she'll hear Noah Averbach-Katz wanted to put diabetes front and center and make a movie that didn't feature it in the background. So while I didn't plan, as I said, you know, back to back here, I think it's an interesting contrast. Of course, the other big contrast is that Noah's movie is self-funded, it is on Kickstarter, I am going to link that up right here in the show notes. It'll be at diabetes connections.com. Very easy to get to, as we are taping the Kickstarter is still going on. But if you're listening to this after it is ending, the deadline is March 24 2022. And as you'll hear, he's already exceeded his goal. And we'll talk about how that happened. But it doesn't mean that he still doesn't need the money. This movie is expensive, all movies are expensive, and he shares about where the money will go, even as he has exceeded the goal. So if you are so inclined, I will link that up. You can head over there. There's a preview of the movie and more information. Noah was diagnosed with type one as a teenager, he will share that story. He's an actor, he has been featured in Star Trek Discovery. That's just one of the parts that he has had. And as he mentioned, he is married to Mary Wiseman, who has a starring role in Star Trek Discovery. When they got married in 2019. The New York Times did a write up and I will include that because it's a beautiful story. It's really well written. It's a lot of fun, but I will just share the headline here a life frequently apart, but an enterprise they'll boldly take on. There's a lot of Star Trek in this family. I do need to warn you know what is pretty blunt about diabetes. We all talk about this in different ways. Bu

It's "In the News..." Got a few minutes? Get caught up! Top story this week: Non-profit insulin announced, Tandem issues warning on some pumps, a common blood pressure med may help T1D, a potential new treatment for retinopathy and a PGA player misdiagnosed w/T2D speaks out -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Non-profit drugmaker Civica expects to launch lower-cost versions of insulin in the United States. Civica said it would produce three copycat versions of insulin, and make them available at roughly the same price for all customers, once approved by U.S. health regulators. The company's products, which would be available as both vials and pre-filled pens, are biosimilars to Sanofi Lantus, Eli Lilly's Humalog and Novo Nordisk's Novolog. The maximum price would be no more than $30 per vial and no more than $55 for a box of five pen cartridges. Civica, which was launched by seven health groups to make essential medicines available at affordable prices, expects to file for regulatory approval in 2023 with products available in 2024. https://www.saltwire.com/atlantic-canada/news/civica-aims-to-launch-low-cost-insulin-in-us-by-2024-100701260/ XX Tandem has issued an urgent field safety notice. This in Europe ONLY and is for the t-slim X2 pumps with Basil IQ technology. According to the notice, a user could inadvertently program and confirm a basal rate with an incorrectly placed decimal point. That could mean giving too much or too little insulin. Tandem says you can continue to use the pump after confirming basal rates are correct. A software update is coming. Again, this is Europe only and this is NOT an issue for any pumps on Control IQ https://www.drugdeliverybusiness.com/tandem-diabetes-warns-on-some-tslim-x2-insulin-pumps/?fbclid=IwAR0dV04W49iQ1LavAIQMkpleif77XiVqKq7ZrhUiFTrpylem-ZHIByRN8nw XX Interesting new potential treatment for diabetic retinopathy. Retinopathy happens when the disease damages tiny blood vessels in the eye, reducing blood flow to nerve cells in the retina. Treatment can be injections or laser surgery. These scientists are looking at photo-bio-modulation – which involves irradiating the eye with far-red to near-infrared light. This increases oxygen-rich blood flow to the retinal cells. They use an LED contact lens to get the light exactly where its needed. No human tests yet.. so it's a far way off. https://newatlas.com/medical/led-contact-lens-diabetes-blindness/ XX I don't have much of an update about diabetes aid to Ukraine except that it's still very much needed. If you're so inclined, we'll link up where you can donate. One partnership I didn't mention last week is one between the Ministry of Health of Ukraine, a group called Direct Relief, and the International Diabetes Federation. They are working closely together to understand where supplies are short, secure donations within and deliver them quickly to where they're needed. Lots of links to vetted organizations in the show notes and here on our fb page. https://sparearose.org/ https://www.jdrf.org/blog/2022/03/02/helping-the-diabetes-community-in-ukraine/ XX The ordinary blood pressure medication verapamil continues to show benefits in treating type 1 diabetes. Patients taking verapamil required less insulin two years after their type 1 diagnosis and also showed evidence of other surprising benefits. These researchers caution that their study is small and needs to be confirmed by larger clinical studies. There are a few other going on right now.. but the preservation of some beta cell function is very promising. https://www.uab.edu/news/research/item/12670-an-oral-medication-shows-benefits-treating-type-1-diabetes-for-at-least-two-years-after-diagnosis XX Two pieces of good news about insurance coverage. Our friends in Ontario, Canada will finally get CGM coverage. Starting March 14th the Assistive Deices Program will cover funding for a CGM and related supplies for people with type 1 . https://www.bayto

When Pixar's new movie, Turning Red premieres, the diabetes community will probably enjoy the story, but we'll be looking very closely at a couple of background characters. There are two with diabetes technology on their arms Diabetes isn't part of the plot here, but it's very visible. We can thank Susan Fong for that. She's what's called the Dailies and Rendering Supervisor for Turning Red. Fong lives with type 1 and she's the one who asked to put diabetes into the movie. We talk about the team effort to get these characters on screen, the balance of math and art that is both diabetes and movie-making and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Stacey Simms 0:00 Diabetes Connections is brought to you by Omnipod. Simplify life with diabetes. by Dexcom. Take control of your diabetes and live life to the fullest and by Club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week when Pixar's new movie Turning Red premieres, the diabetes community will probably enjoy the story. But we'll be looking very closely at a couple of background characters. There are too with visible diabetes technology. Diabetes is not part of the plot here, which is kind of the point. Susan Fong 0:45 And sometimes I think that's important. I know a lot of folks get frustrated by the number of questions. They're asked about diabetes, or can you eat that? Should you be eating that? What's that thing on your arm, and sometimes it's just nice to be who you are, and have it not be a part of. Stacey Simms 1:01 That's Pixar's, Susan Fung. She lives with type one. And she is the person who asked to put diabetes into Turning Red . We talk about the team effort to get these characters on screen, the balance of math and art that is both diabetes and moviemaking, and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, always so glad to have you here. If you are new, we aim to educate and inspire about diabetes with a focus on people who use insulin. And how cool was it to see people who use insulin in the Turning Red trailer when this came out a couple of months ago, and you know, there was that first trailer, the little teaser, where we saw one child with what looked like a pump infusion set maybe on her arm. We all went bananas. But then the second trailer came out and we saw another kid with diabetes technology. It looked like a Dexcom CGM on her arm. And that prompted 1000s of posts and tons of questions. Well, we've got the answers for you this week. My guest is Susan Fung and she is what is called the dailies and rendering supervisor for Turning Red . She'll explain what that means and how this whole process came together. Susan lives with type one she was diagnosed at age five. Her sister also has type one she was diagnosed a few years later. Susan was Pixar as sequence lead on Seoul, the rendering Supervisor of Coco and she's worked on Brave Toy Story three Wally Up Ratatouille, the list goes on and on. I am really grateful that she spent some time talking to me about diabetes and animation and a lot more. But first Diabetes Connections is brought to you by Omni pod. You know, I'm a big fan of choice when it comes to diabetes technology. I get so excited when there's something new. Because if you live with diabetes, whatever type whatever age, you deserve to find the best fit for you. That's just one reason I'm working with Omnipod to help spread the word about their program that makes it so easy to test their system out. It's the Omnipod dash free trial. If you want to try an insulin pump or see what life without tubes is all about, you can now try Omnipod dash free for 30 days. The trial comes with no commitment or obligation, not right for you. No problem, go to diabetes connections.com and click on the Omnipod logo or go to omnipod.com/diabetes connections for details, Terms and Conditions apply for full safety risk information and free trial Terms and Conditions. Visit omnipod.com/diabetes connections. Susan, thank you so much for joining me. I think the whole community just went bananas when we saw the trailers of the teasers for Turning Red . So to talk to you about how this all happened is just a thrill. Thanks for being here. Susan Fong 3:55 Definitely. Yeah, thanks for having me. Stacey Simms 3:56 Let's just j

It's "In the News…" Got a few minutes? Get caught up! Top stories this week include: where to donate if you want to help people with diabetes in Ukraine, a look at cases of COVID-induced diabetes that seem to be temporary, Dexcom gets FDA breakthrough status for use in hospitals, insulin prices mentioned in the State of the Union, T1D college scholarships and learning more about a non-invasive glucose monitoring system called SugarBeat. -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story.. a lot of you were asking about help for people with diabetes in Ukraine. I didn't jump right into this last week because I get very concerned about scams. We hate to think anything about diabetes isn't on the up and up.. but we need to be careful. I was really glad to see Insulin for Life, which is very well known and well-run, stepping in here. And easy way to donate to them is through Spare a Rose for Ukraine. This is the annual campaign centered around valentine's day that usually runs through February.. they're extending it through March. All donations will be directed to Insulin for Life, a registered charity with over two decades of experience providing insulin and diabetes supplies to under-resourced countries, and responding to emergencies. Their international consortium and network in Europe, with partners in Ukraine and neighboring countries, has supplies ready to go if, when and where needed. https://sparearose.org/ https://www.jdrf.org/blog/2022/03/02/helping-the-diabetes-community-in-ukraine/ XX As doctors learn more about people who develop COVID-related diabetes they're finding blood sugar returns to normal a few months later. Researchers studied 600 patients who showed signs of diabetes while hospitalized for COVID-19, including 78 with no previous diagnosis of diabetes. Compared to patients with pre-existing diabetes, many of the newly diagnosed patients had less severe blood sugar issues but more serious COVID-19. Roughly a year after leaving the hospital, 40% of the newly diagnosed patients had gone back to blood sugar levels considered non-diabetic. https://www.reuters.com/business/healthcare-pharmaceuticals/covid-related-diabetes-may-be-temporary-racial-disparities-widen-with-omicron-2022-02-25/ XX Scotland has nearly 2-million people in a huge ongoing COVID study. The latest info from that shows no association with a COVID infection causing type 1 diabetes in children less than 16 years old. Type 1 in children increased to about 1.2 times the average during the pandemic but it doesn't seem to have been caused by COVID. The US CDC has said otherwise, that there does seem to be a causal link between COVID and type 1. In all the studies so far, getting a COVID vaccine was not associated with incidence of type 1 diabetes https://www.medscape.com/viewarticle/969166 XX Good news about using the Dexcom CGM in the hospital. The FDA has granted Breakthrough Device Designation for Dexcom for healthcare professionals to monitor and manage glucose levels… in adults who use insulin while in the hospital. We first talked about this in 2020 when the FDA temporarily allowed hospital CGM use because of COVID. Dexcom created a special page on their website to provide resources to clinicians.. I'll link that up. https://www.dexcom.com/hospitalcovid-19 XX Researchers say they're making progress into amyloid, a key molecule in the pancreas that contributes to type 2. For the first time, scientists say they've uncovered the step-by-step changes that take place in a molecule known as human islet amyloid polypeptide. It's helpful in the body until it changes into a more damaging form. The researchers said their findings, raise the possibility of new treatments for type 2 diabetes and other amyloid-related diseases such as Alzheimer's https://www.medscape.com/viewarticle/969265 XX There is a huge psychological barrier against starting insulin for those with type 2. A new web-based resource is hoping to help

In February, the FDA approved the Eversense E3 for 180 day wear. That means you could have a CGM working – with no sensor changes needed – for up to six months. That's been available in Europe for a while, but in the US it's been a maximum of three months. As you'll hear, the people at Eversense have even bigger goals. This week, you'll hear from Senseonics Chief Medical Officer, Dr. Fran Kaufman. We get the basic info about the device, the plan for working with pump companies, a look ahead and much more. Imagine one year without a sensor change! Dr. Kaufman is also a practicing endocrinologist and she's been seeing patients for more than 40 years. She has a passion for this community and a lot to say about what truly helps patients thrive with diabetes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. .. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms This week Eversense is an implantable continuous glucose monitor. It just got FDA approval for a 180 day where that's six months with the dose sensor changes. Something else that makes it different. It can vibrate to let you know if you're low or high. Dr. Fran Kaufman 0:39 And then people really, really enjoy that long term concept, as well as vibratory alerts. We've got people who work on the tarmac at the airport and they can't hear anything. So the only way they can actually do this is with the vibratory alerts. Stacey Simms 0:52 That's the company's chief medical officer, Dr. Fran Kaufman, we go in depth on the Eversense system talking about how it all works, accuracy, and looking ahead to whether they'll partner with any insulin pumps for a closed loop. And they have big plans to make the system last even longer. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Oh, we so glad to have you here. We aim to educate and inspire about diabetes with a focus on people who use insulin. If you are new, my son was diagnosed with type one right before he turned two that was back in 2006. He is now 17 years old. My husband lives with type two diabetes. I don't have diabetes, I have a background in broadcasting. And that is how you get the podcast. And I have been doing this podcast since June of 2015. I looked back in the show archives. They're all on the website. You can use a search box to find what you're looking for. But I looked back and we first talked to Eversense in October of 2018. We actually talked about Eversense at that time, not with the company. I talked to Darryl Greene. He was one of the first people in the US to get the sensor implanted. He is a news anchor. And he did it for his show, he showed the video of the implant the whole thing. I will link that up in the show notes so you can hear what Darrell had to say at the time and see an early version of Eversenseit has changed a bit since then. But as you will hear this week, it is subcutaneous it's just under the skin. And that is where the Dexcom or libre or Medtronic Guardian sensor lies, but you can't insert it yourself. It is a quick outpatient procedure. It's minor but it is still a procedure. The flip side that's it for six months, no supply orders, no changing sensors. My guest here to talk about it and answer a bunch of your questions is Dr. Fred Kaufman. She is the Chief Medical Officer of sin psionics. The company that makes Eversense she is a pediatric endocrinologist who still sees patients and I could take the whole episode to read off her accomplishments. She's been in practice for 40 years, director of the comprehensive childhood Diabetes Center and head of the Center for endocrinology, diabetes and metabolism at Children's Hospital Los Angeles, former president of the American Diabetes Association, chair of the National Diabetes Education Program, on and on. And she has authored over 250 Scientific manuscripts and numerous books. I love talking to people like Dr. Kaufman, because yes, she's a very accomplished woman. She obviously knows her stuff. But you will hear her passion for this community. She is really in it to help all patients living with diabetes. Quick note, I realized, as I was listening back, I do that a lot with these interviews for e

It's "In the News…" Got a few minutes? Get caught up! Top stories this week include: a look at Vitamin D in newly diagnosed kids with type 1, new study about bariatric surgery, type 2 and COVID, endos are the top specialty adopting telehealth and a look at a new movie about type 1 - find out why it also has backing from the Star Trek community! -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! OMNIPOD DEXCOM Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Diabetes supplies can really add up and all that pump and CGM stuff or even shots and wipes and strips can clutter everything up. I've got a great new guide to help you out. It'll get you started and keep you organized. That's totally free and it's over on the podcast homepage. XX A new study adds to the idea that Vitamin D might help with type 1 diabetes in kids. These researchers look at young people ages 10-21 and found that a supplement of Vitamin D2 may improve insulin sensitivity and slow the increase of A1C for those newly diagnosed. This was over the course of a year. Very small study, fewer than 40 kids and teens, and all of them diagnosed for three months or less. A lot more to learn here.. but the study is in the Journal of the Endocrine Society. https://www.healio.com/news/endocrinology/20220221/vitamin-d2-supplement-may-slow-progression-of-newonset-type-1-diabetes-in-children XX This is more business news.. but something to keep an eye on.. RosVivo has signed with Eli Lilly for commercial development. Rosvivo has a drug said to be a game changer to treat diabetes and obesity. Lilly will now review and move it forward. The drug is said to restore the function of beta cells that secrete insulin, the cause of diabetes, and at the same time lowering insulin resistance. Animal studies only but we're keeping an eye on this one. https://finance.yahoo.com/news/rosvivo-therapeutics-inc-signed-material-125200372.html XX Provention Bio has resubmitted the Biologics License Application (BLA) for teplizumab. This is the drug that shows a delay of clinical type 1 diabetes for three years. The FDA said "no" last year.. but it did so in a way that left the door open, so Provention has done what's been asked and is now resubmitting. The CEO says quote - "We continue to proceed with a sense of urgency, recognizing that significant unmet need exists for patients and their caregivers." https://www.empr.com/home/news/drugs-in-the-pipeline/provention-bio-resubmits-bla-for-teplizumab-to-delay-type-1-diabetes/ XX The link between high blood pressure and diabetes seems to come down to a small protein cell. An international team shows this glucagon like peptide called GLP-1 pairs up the body's control of blood sugar and blood pressure. Doctors have known for a long time that high blood pressure and diabetes go together, but this is the first time the reason for that has been found in the body. GLP-1 is released from the wall of the gut after eating. It also stimulates a small sensory organ in the neck. These researchers say GLP-1 is just the start for more study. https://scitechdaily.com/long-standing-enigma-finally-cracked-link-discovered-between-high-blood-pressure-and-diabetes/ XX More support for bariatric surgery as a treatment for type 2 diabetes. A study found that adults with obesity who had weight loss surgery and achieved "substantial weight loss" before contracting COVID reduced their risk for severe infection by 60% compared to those who didn't have surgery. The study was conducted by researchers at the Cleveland Clinic. Previous studies have found that in obese patients with type 2, bariatric surgery sends it into remission more than 75% percent of cases. https://blogs.bcm.edu/2022/02/21/bariatric-surgery-helps-with-diabetes-leads-to-better-covid-outcomes-study-finds/ XX Throughout the COVID 19 pandemic, endocrinologists have had the highest rates of… telehealth adoption. This study released by Doximity – we've spoken to them on the show – looked at telehealth claims from January 2020 to June of 2021. As expected, younger physicians used telehealth more than their older counterparts. And they say the research shows that telehealth can successfully help manage diabetes – and that it even lowers A1C in people with type 2. They don't say why.. but I'd think it's because it's easier to get a visit in remotely. Interesting

Lauren Bongiorno was diagnosed with type 1 as a child and growing up, she showed every sign of success. She was a division one athlete, playing soccer in college and achieved the lowest A1C her endo had seen in a college student.. but while her care team celebrated that 5.7, she was miserable. Lauren shares how she took control and got that happiness back. She's now a Diabetes Coach at her company, Risely. We talk about some common pitfalls, the pressure to be perfect and what coaching really means. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! OMNIPOD DEXCOM ----- Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921 Where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, Lauren Bongiorno was diagnosed with type one as a child and growing up she showed every sign of success. She was a division one athlete playing soccer in college and achieved the lowest A1C her endo had ever seen in a college kid. But while her care team celebrated, she was miserable. Lauren Bongiorno 0:41 And I was sitting there and it was like literally an out of body experience because I'm watching like the doctor, high five, my mom and my five each other and I was like, I'm not happy, I'm not happy. Stacey Simms 0:52 Lauren shares how she took control and got that happiness back. She's now a diabetes coach. We talk about some common pitfalls, the pressure to be perfect and what coaching really means. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. I am always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. As I'm taping the intro to this episode. I am like you sifting through some FDA approvals these seem to be coming in fast and furious now or at least as fast and furious as the FDA does anything. But after a very long logjam, you know, this is all stopped up by COVID. It really seems like things are moving along. So to that end, this episode will not focus on tandems mobile bolus, which was just approved, you know, bolus by phone or the ever since CGM 180 day where approval. Those were the two biggies over the last week. And I am going to focus on them in upcoming episodes ever since should actually be next week. And Tandem a couple of weeks after that. As always, if you'd like to get your questions asked please join us in the Facebook group Diabetes Connections, the group if you're not on Facebook, no problem. Shoot me an email Stacey at diabetes connections.com. I have my own set of questions. But I always want to hear from you. And your questions are always fantastic. So please send them in. But there is a lot more to diabetes than technology. You all know that. And I wanted to share Lauren Bongiorno's story, because I think this really resonates for parents of kids with type one. And for adults with diabetes, nobody's harder on us than we are on ourselves, right and the pursuit of perfection. It's just gonna mess you up. I'll let Lauren share her story. But just for background, She is the CEO and head coach at a company she founded called Risely that's a bit of a play on how in diabetes arise isn't a good thing. You know, an arrow up on your CGM, a higher A1C , their website says type 1 diabetes has given rise a bad reputation. But we think it's time we reclaim it. I think that's really clever. And I think this is the first time I've spoken with a health coach on the show. So we talk about what exactly that is, and why somebody would choose to work with a coach along with a medical provider. Here's my talk with Lauren Bongiorno. Lauren, thanks for spending some time with me and my listeners. I'm so excited to talk to you. Lauren Bongiorno 3:33 Oh, thank you so much for having me on. Stacey. I'm so looking forward to this conversation. Yeah, I Stacey Simms 3:38 feel like I've we've connected and I've seen you, you know, all over social media. So I'm, I'm really excited to kind of hear more of your story and share your experiences. Because just the little bit that I know, I feel like you're kind of the embodiment of why perfect doesn't always work out with diabetes, if I could say that. Lauren Bongiorno 3:56 Yeah, I think you can say that. And it's so interesting, because I think that if there's one thread of my entire life that I can really look at,

It's "In the News..." Got a few minutes? Get caught up! Top stories this week include two big FDA approvals! Tandem's Mobile Bolus and Eversense 180 day sensor both get the okay, we're looking at earlier detection of T1D in kids, there's a new discovery around a protein that might help T2D, info about Spare a Rose and Omnipod drops a hint about a crossover with a popular Nintendo game. Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! OMNIPOD DEXCOM FB LIVE: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Diabetes supplies can really add up and all that pump and CGM stuff or even shots and wipes and strips can clutter everything up. I've got a great new guide to help you out. It'll get you started and keep you organized. That's totally free and it's over on the podcast homepage. XX Our top story this week – big movement from the US FDA, two approvals we've been waiting for. The first, Tandem Mobile bolus – what I've been calling bolus by phone. As expected, company says when released, this will be no additional cost for in-warranty customers through a remote software update. Limited launch in the spring, followed by expanded launch this summer. It's compatible with both iOS and Android, although limited to just a couple of models right now. This is a very important step not just for customer convenicen but as Tandem moves forward with it's new hardware line including Mobi will need an external device for full control. https://www.tandemdiabetes.com/landing-pages/remote-bolus XX The second FDA approval came through for The Eversense E3 continuous glucose monitor. This 180-day implantable sensor will be available later in 2022. If you're not familiar, you have the sensor, inserted under the skin of the upper arm (and removed) every six months by a trained healthcare provider. There is a rechargeable transmitter which vibrates on the body for highs and lows.. and a mobile app. The sensor requires two calibrations per day for the first 21 days of wear. After that it requires one calibration. Lots of questions here and I'm talking to these folks for an upcoming episode.. look for that in about two weeks. https://diatribe.org/180-day-implantable-cgm-eversense-e3-approved-fda XX Saw an interesting post from Omnipod this week on IG.. All about Pat Podder® - the caption says she "is a long-time member of the Pod Squad who loves a good DIY project, going swimming, and to explore new places." Take a look at this animation, along with the hashtag they used.. Animal Crossing.. are we about to see a gaming crossover? Insulet says an announcement is coming Thursday of this week, so if you're listening to the podcast it may have already happened.. I'll follow up. https://www.instagram.com/p/CaA_5rEsyMH/ XX Big push in Germany to get doctors to screen very young kids for type 1. This group conducted the world's largest population based screening for type 1 diabetes in children so far. Since 2015, any child aged 2–5 years in Bavaria, Germany, could have their blood tested for islet autoantibodies. These show early stage type 1 diabetes years before high blood sugars and other symptoms. More than 90-thousand kids have been tested and point 31 percent (.31%) have been diagnosed. Next up is to take a deep dive into the potential cost savings and increased quality of life compared to what happens without these early screenings. https://medicalxpress.com/news/2022-02-early-diabetes-children.html XX It's a mouse study.. but good potential here for a drug to treat type 2 diabetes. It works by amplifying a protein that has a positive effect on insulin. The protein is called Swell-1 and it's vital for normal insulin secretion from pancreatic cells. And, SWELL-1 activity seems to be significantly disrupted in people with type 2. Fixing that seems to restore both insulin sensitivity and insulin secretion. And it does this without lowering blood glucose when that's not needed. Long way to go but promising.. https://newatlas.com/medical/new-drug-target-diabetes-metabolic-disease-swell1/ XX The Spare a Rose campaign was back – focusing on Valentine's Day but continuing through February. The idea here is that instead of buying a dozen roses.. you buy 11 and donate the value of that last flower to help someone with diabetes. Since starting in 2013 Spare a Rose has raised almost 400-thousand dollars.. most

Last fall, Sigi pump received Breakthrough Device Designation from the US FDA. Although it's still a long way from being released, Sigi is very intriguing; it uses some of the best parts of existing pump systems. Pim Von Wesel is Co-CEO of AMF Medical, the company that makes the Sigi Pump. We'll talk about what makes this system unique, which partners they're eying for collaboration and the timeline for submitting to the FDA really looks like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, it's called Sigi pump. And last fall it received breakthrough device designation from the US FDA, there's still a long way to go before this tubeless rechargeable pump could be on the market. And company leaders say that's okay by them. Pim van Wesel 0:37 We're biding our time to make it short is excellent in every respect, technically, from a usability point of view, of course, which has a huge focus to us lowering therapy burden, and also just being able to produce it in sufficient quantities. Stacey Simms 0:51 Pim van Wesel is Co-CEO of AMF Medical, the company that makes the Sigi pump, we'll talk about what makes this system unique, which partners they're eyeing for collaboration, and what the timeline for submitting to the FDA really looks like, This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. Before we jump in, I want to give a big shout out to the amazing people in our Facebook group. If you're not there, it's Diabetes Connections, the group and I just want to single them out, because I think that it is the smartest diabetes Facebook group that's out there. I know I'm a little biased. But you know, it's not the kind of group that's going to tell you how to eat or how to dose or you must do this, or how dare you do that. As you know, if you listen to the show, that's not our deal at all. And I just want to take a moment because I've been asking the folks in there many of whom have lived with diabetes for 50, 60 years, many of whom work for technology companies, many of whom have been blogging about diabetes for many, many years. And I've been bringing them questions that have come up in my local group, things like cannula length, making a difference, some questions I had about summer camps for this year. And they all also have fabulous conversations. So I know we're all if you're on Facebook, you're in a ton of groups already. I do think that it's a really good one. If you'd like to hear from people who have lived with this condition for a long time who are very knowledgeable and frankly, very opinionated, which I like a lot. I do run a very tight ship. I do this in my local group as well as this one, you're not going to get away with any nonsense. Any weird stuff, a snake oil. Yeah, we will have none of them. But it's a great group. And I just was given them a shout out because they've been very, very helpful, especially lately. Okay. Sigi pump caught my attention when it received that breakthrough designation that I mentioned. And to be clear, that means the FDA will try to speed it through the process. It does not mean it's approved for that it's guaranteed approval. And Sigi by the way is S-i-g-i. I did share some photos of it in the Facebook group. And my guest is Pim van Wesel , the CO CEO of AMF medical, that is the Swiss company behind Sigi pump. They are very early on here. Clinical trials have not yet started, but they do plan that when they get through the process to launch in the US first while it looks a bit like an omnipod, but the pod part is reusable. You recharge it as needed, and they give you two so you don't have to stop pumping while you're recharging. One of them. The only disposable part is the infusion set, although they call it something else, the part that connects to the body. Lots more information about Sigi in my interview with Pim van Wesel Pim thanks for joining me. I am excited to find out more about this product in this company. Thanks for coming on the show. Pim van Wesel 3:54 Thanks for having me. Stacey. Very excited to share what we

Every week "In the News…" brings you the top stories and headlines around the diabetes community. Top stories this week: A new treatment is being studied to help prevent hypos, cannabis use may decrease women's risk of type 2, examining Veterans Affairs claims for T1D & Agent Orange, better prevention for T2D and heart disease and which athlete at the Winter Olympics was diagnosed with type 1 as a teen? -- Join us LIVE on Facebook & YouTube every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Check out my new guide with top tips to clear your diabetes clutter. Everything from how to start to where to donate and how to keep it from taking over your house. Head over to the home page to get organized. XX Our top story.. moving forward to find a daily therapy to slow or prevent low blood glucose in people with type 1. This is from diabetes-focused life sciences company Zucara Therapeutics. They're calling the drug ZT-01 and in theory it could restore the body's ability to release glucagon. Long way to go here, but reducing hypoglycemia is obviously a great outcome due to the many risks lows can create. Zucara will now move ahead with it's proof-of-concept clinical trial in people with T1D. The company expects to publish the findings from that study closer to this summer. https://www.biospace.com/article/zucara-reveals-hopeful-preclinical-data-in-type-1-diabetes-/ XX Part of the 2021 National Defense Authorization Act means a close look at type 1 in the VA. It mandates a report on disability compensation claims submitted by Vietnam War veterans who have Type 1 and were exposed to an herbicide agent during their service. The VA recognizes that Vietnam veterans' Type 2 diabetes can be related to Agent Orange. But it requires veterans with type 1 to provide evidence. There are some challenges here: The VA's claims decision data only goes back to 2003 and they track Type 1 and Type 2 with the same diagnostic code, they don't distinguish between the two conditions. In 2020, diabetes represented roughly 6.5 percent of all service-related conditions for which Vietnam War era veterans received compensation. gao.gov/products/gao-22-105143 XX New study of gestational diabetes shows it recurs for nearly half of women who've had it before. These doctors say little is known about the risk factors for recurrent gestational diabetes. Part of the problem is that they just changed criteria for diagnosing it. In this study about 8-percent of women had a history of gestational diabetes. Of those, almost 50-percent had it recur and just over 7-percent developed type 1 or type 2 between those pregnancies. https://www.healio.com/news/endocrinology/20220208/risk-factors-differ-for-first-time-recurrent-gestational-diabetes XX What's the link between weed and a lower risk of type 2? First.. this study only showed such a link in women NOT in men and only in heavy users. In this study that means using cannabis at least four time in the previous month. No differences in the prevalence of type 2 in men who were light or heavy cannabis users versus nonusers. These findings come from a large 5 year study that ended in 2018 and in which people self-reported their use. These researchers say the gender difference was also seen in animal models. Expect more study on this one. https://www.medscape.com/viewarticle/968186 XX More good outcomes with SGLT2 inhibitors and GLP-1 receptor agonists. These drugs are a mouthful but new research links them with lower chances of potentially fatal heart problems in people with type 2 without established heart disease. They compared these newer meds to the risks in people using more traditional therapies, such as metformin. The researchers showed the odds of developing heart failure was 51 percent lower for people using SGLT2 inhibitors, 18 percent lower for GLP-1 users and 57 percent lower for people using both drugs. The newer drugs are prescribed less and these researchers say we need to look at why when the newer ones show better outcomes. https://medicalxpress.com/news/2022-02-diabetes-drugs-thousands.html XX Some tough numbers about depression and diabetes. In the US.. about 30-percent of people with either type 1 or type 2 have depressive symptoms and 11-percent show signs of major depressive disorder. This lines up with studies f

People with diabetes were encouraged to get a COVID vaccine early on when the shots were released. But what happens when you live with type 1 and another condition where the vaccine recommendation is more complicated? Molly Schreiber lives with T1D and rheumatoid arthritis. Her doctors told her to absolutely NOT get a COVID vaccine due to treatment she was taking for the second condition. She was able to eventually get vaccinated then, despite taking precautions, she and her entire family got the Omicron variant. They're fine now and Molly has a lot of good info to share. She also has several family members with type 1 and has a lot to say about how we care for older people with T1D. Molly works at the Community Manager for Savvy Coop. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Type 1 Diabetes with Other Autoimmune Diseases Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, people with diabetes were encouraged to get a COVID vaccine early on, when they were released. But what happens when you live with type one and another condition where the vaccine recommendation is… complicated? Molly Schreiber 0:35 And I messaged my rheumatologist and I said great news. My hospital has the vaccine in I can get an appointment. You know, I was super excited. And she called my cell phone immediately and says You could not get that vaccine and it was a gut punch. What do you mean, I can't get this vaccine, Stacey Simms 0:52 Molly Schreiber lives with type one and rheumatoid arthritis, she was able to eventually get vaccinated, then despite taking precautions, she and her entire family off the omicron variant, they're fine. And she has a lot of good information to share. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. And one of those people had a really bad low last night, as most of you know. And if you are new, I will explain my son, Benny was diagnosed with type one right before he turned two, he is now 17. We use the control IQ system with Tandem and Dexcom. And I gotta tell you, it has been a while since that urgent low has gone off on my Dexcom app. And I really don't remember the last time he had an urgent low that he didn't treat pretty quickly. You know, he very rarely asks for my help. We are at the point now where I have turned off all of the Dexcom alerts except that urgent low. But in the middle of the night, it was like one o'clock in the morning it went off. And I don't know, you know, usually I would have waited and just said maybe he's got it. He always had stuff in his room. But it was It wasn't in 55 It was 42. So I said, you know, I'm gonna just go check on him. And they brought up a juice box like I have done a bajillion times, you know, when he was little, it's so funny. I gotta say, you know, the juice box used to seem like a big deal, a big amount, I should say. But it looks so tiny. He's now like six feet tall, but I brought it upstairs. And it was immediately clear that this was a real low. This wasn't a compression low. He wasn't leaning on the Dexcom. He was disoriented, he was sweaty, he was super hungry. So he drank the juice box, I got him some crackers. And then I sat with him for a little bit. And he started to kind of come back to himself. But he was so hungry. And you know what this is like, I don't know about you. But he was sometimes I really try if I'm with him, which isn't the case all the time anymore. I tried to say you know, you've had you've had your 15 or 20 carbs or you know, when he was little you had your four to eight carbs. And let's just sit because you know, you're going to be okay. Now, you know, you're not going to be hungry in 15 to 20 minutes. But man, that urge to eat. I mean, I know his brain is screaming at him. So I was like, you know, forget this. I went downstairs and I got him some more food. I figured I can always give him more insulin for it and who knows. He just really still felt bad. So we overtreated which, again, we haven't done it a long time totally overtreated. And, you know, he finally felt better and was able to go back to bed. But you know, my adre

Every week "In the News…" brings you the top stories and headlines around the diabetes community. This week: Omnipod 5 is approved, T1D families win a NYC field trip lawsuit, the first drug to delay type 1 DX gets a second chance and getting glucagon without a prescription -- Join us LIVE every Wednesday at 4:30pm EST on Facebook and 4:45pm on Instagram Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Check out my new guide with top tips to clear your diabetes clutter. Everything from how to start to where to donate and how to keep it from taking over your house. Head over to the home page to get organized. XX Our top story.. Omnipod 5 is approved. The US FDA has okayed the system more than a year after it was submitted – held up like a lot of other diabetes tech due to COVID. This is a hybrid closed loop which means you still to give insulin for meals but it will work hard to keep you in range. It's the first system approved with phone control and with a bit of A-I.. the system uses what it learns about you to improve dosing. I spoke to the company's medical director for the podcast this week and I recommend you listen to that episode for tons of detail on how the system works, what makes it different from what's already on the market and details about insurance, Medicare and a lot more. XX Medtronic is sending out a letter this week to everyone who received one of its new or replacement insulin pumps within the last six months to remind them to make sure they have saved their basal insulin rates on their devices. This is considered an "urgent medical device correction" notice and was prompted by a series of injuries recently due to the use of pumps that had not been properly programmed.. they came out of the box with no basal rates which is normal.. and for whatever reason, users didn't know to enter them. Moving forward, Medtronic will look into making their pump menus more user-friendly and updating the educational materials that come with the box to be more clear. It's a good reminder that whatever pump you use, keep track of the programming – we take photos of my son's pump settings with his phone and back the photos up periodically. https://diatribe.org/medtronic-issues-urgent-basal-insulin-reminder-pump-users?utm_source=facebook&utm_medium=organic&fbclid=IwAR0Gsn8KugMTcuzvFKXL7xfZeUgSeHJ9BZzqi7lL38bpuG1qyFrp59i3ooE XX Big ruling in favor of kids with diabetes and other disabilities.. federal court has found that New Yrok City's Department of Education routinely denies students with diabetes access to field trips and bus transportation. Three sets of parents of T1D kids and the American Diabetes Association sued the district after no care was provided for students on field trips and that the policy of "we'll call 911" was insufficient for bus riders. The court has ordered the district to train bus drivers and attendants in the use of glucagon and will hire nurses to help on field trips. Many states don't mandate nurses on fields trips, just trained staff, but NYC does and that made it very difficult for them to follow their own rules. Worth noting, these parents did not seek monetary damages, but filed the suit with the hope of policy change. https://www.diabetes.org/newsroom/press-releases/2022/federal-court-rules-children-with-diabetes-in-nyc-denied-equal-access-to-field-trips-bus-transportation XX For the second year in a row, in 2021 - more than 100,000 Americans died from diabetes. The story, as reported, is that now Congress should overhaul diabetes care and prevention, promoting consumption of healthier foods, ensuring paid maternity leave, put taxes on sugary drinks and expand access to affordable housing, among other areas. But – and this is just my opinion – they could also tackle the price of insulin and other diabetes medications and supplies. That's mentioned in this report, but well down the list and isn't what most of the headlines have picked up on. About 37 million Americans, or 11% of the population, have diabetes, and one in three Americans will develop it in their lifetime if current trends continue, according to the commission. https://www.reuters.com/world/us/exclusive-us-diabetes-deaths-top-100000-second-straight-year-federal-panel-urges-2022-01-31/ XX Another chance for teplizumab. The FDA says Provention Bio can resubmit its ap

The US FDA has approved Insulet's Omnipod 5 Automated Insulin Delivery System. This system was submitted more than a year ago but has been delayed due to COVID 19. Stacey talks to Dr. Trang Ly, Senior Vice President & Medical Director at Insulet Corporation who explains what makes this system different from the other AID systems on the market, what phone control means, what the roll out will look like, insurance issues, Medicare and more. Omnipod 5 FAQs from Insulet DiabetesMine's write up of Omnipod 5 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Learn more about Dexcom help for veterans here Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921 Where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, the US FDA approves Insulet's Omnipod 5 automated insulin delivery system. This was submitted more than a year ago but has been delayed due to COVID 19. Let's hope this approval signals at least the beginning of the end of that logjam at the FDA. Welcome to another week of the show. I am always so glad to have you here I am your host, Stacey Simms, and we aim to educate and inspire about diabetes with a focus on people who use insulin. If you are new to the show, my son was diagnosed with type one right before he turned two back in 2006. He is now 17. My husband lives with type two diabetes. I do not have any kind of diabetes. I have background in broadcasting. And that is how you get the podcast. And for this episode, I am so excited to speak to Dr. Trang Ly, Senior Vice President and medical director at Insulet Corporation. Insulet, of course, makers of the Omnipod. I asked for questions within our Facebook group. It's Diabetes Connections, the group and boy to do come through. But because Dr. Ly is part of the medical side of Insulet, I'm sure you understand there are some questions she just can't answer she it's not her realm of expertise. But I promise we will follow up in the weeks and months to come. And I will do a deep dive into what is such a huge story for our community. I am always so excited to see more choice for people with diabetes and automated insulin delivery is a game changer. Let's go through the basics. Because while many of you just want to get to "when can I get this in my hands. And I've used this product for years. And it's basic forms, I just want to get the loop.." Let me just take a quick second and set the table because there are a lot of people new to pumping and to pods. And I just want to be absolutely clear. And this is going to be very simplistic Dr. Ly we'll get into many more details. But the pod is what sits on the body. That's what holds the insulin and infuses the insulin into the body. There are no buttons, there's no display, there is a separate handheld controller. This could be a phone, we will talk about that. And that is how you control the pod when it comes to giving insulin for meals, you still must give insulin for meals with this system. With Omnipod 5, you also have the Dexcom G6 that is the continuous glucose monitor. The pod and the CGM work together, it very simplistically gives you more or less insulin to try to keep you in range. There are similar systems on the market already. The Medtronic 670 was the first like this in the United States. Now they have their 770 G system. Tandem has the control IQ system. For the record. That is what my son has used since January of 2020. And Omnipod system is a little different on these systems all have differences from one another. But as you'll hear the Omnipod system is the first in the US that will actually learn from you. And we'll talk about what that means Omnipod 5 is going to launch through the pharmacy channel just like previous products and will still have no contract. And they are offering what they're calling a limited market release. So this is not going to be available tomorrow to most people Insulet has a Frequently Asked Questions section on their website that I got to say it is one of the most robust I have ever seen in my 15 years of diabetes. So please go there. If you don't hear your question answered by Dr. Ly. I'm going to link it up at diabetes connections.com There will be a link in the show notes. And as I said, we're going to be covering this a lot more this year. And make sure you tune in every week I do a short newscast episode. We do that every Wednesday live at 430 on Facebook and YouTube

Every week "In the News…" brings you the top stories and headlines around the diabetes community. This week: a new look at access to #diabetes meds, a look at stress in parents of children with type 1, Mark Cuban's new online pharmacy is open, can worry contribute to type 2 risk factors? And Lilly gets another slap from the FDA, this time about an Instagram ad. Join Stacey live on Facebook every Wednesday at 4:30pm EST and in Instagram at 4:45pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Check out my new guide with top tips to clear your diabetes clutter. Everything from how to start to where to donate and how to keep it from taking over your house. Head over to the home page to get organized. XX Among people with type 2, minority ethnic groups have more limited access when it comes to newer diabetes medication.. This study used data gathered from 2005 to 2019 in a large clinical trial conducted at Johns Hopkins and other sites across the U.S. They found that compared with white patients, all minority groups were less likely to start newer diabetes medications. Black patients were 20% less likely to start newer medications, and American Indian or Alaskan Native patients, were 50% less likely. The researchers stress the findings were not driven by the patient's income – didn't matter how much money they made. The researchers say the next step is to look at how insurance coverage impacts which diabetes medications get prescribed. https://medicalxpress.com/news/2022-01-minorities-diabetes-medications.html XX Billionaire Mark Cuban has opened up an online pharmacy offering prescription drugs at cheaper prices. Insulin isn't included.. yet.. but there are some diabetes medications listed. Mark Cuban Cost Plus Drug Company says they want to – quote - "bypass middlemen and outrageous markups." Cuban is not the first to enter the market.. it's a highly competitive one with contenders like GoodRx https://www.usatoday.com/story/money/2022/01/24/mark-cuban-cheaper-prescription-drugs/6636901001/ XX Really good write up about the stress of parenting a child with type 1 diabetes.. and what can be done about it. This is in Endocrinology Advisor – they spoke to pediatric psychologists and endos. Familiar stories of no sleep, fear of hypos and of future complications but also some good information about how the stress changes over time and over the child's life. Acknowledging different challenges face parents of very children compared to those of teens. Not a lot of solutions here.. but very good reading about supporting a parent's well being as well as the child's. https://www.endocrinologyadvisor.com/home/topics/diabetes/type-1-diabetes/children-with-type-1-diabetes-and-parents-and-psychological-and-impact/ XX Obesity is a main risk factor for developing type 2 diabetes, but it has not been previously seen as a major complication in type 1 diabetes. However, a new study shows that obesity rates in adults with type 1 diabetes are increasing and mirror the rates in the general adult population. These researchers, also at Johns Hopkins, say adults with type 1 diabetes also now have a higher risk of kidney disease than those with type 2. https://scitechdaily.com/obesity-is-more-common-in-people-with-type-1-diabetes-than-previously-thought/ XX Middle-aged men who are anxious and worry more may be at greater biological risk for developing heart disease, stroke and type 2 diabetes, also called cardiometabolic disease, as they get older. This study used a long-running research project, started in 1961 and mostly including white men. They followed different groups of men through 2015 and measured worry through questions and surveys. Higher worry levels were associated with a 10% higher likelihood of having six or more cardio-metabolic disease risk factors. These researchers say it would be important to follow up to see if these associations exist among women and people from diverse racial and ethnic groups. https://medicalxpress.com/news/2022-01-men-heart-disease-diabetes-factors.html XX Big slap for Eli Lilly from the FDA.. they say an Instagram ad for the type 2 diabetes drug Trulicity was "misleading" and "particularly concerning." Lilly has since deleted the post in question, but the FDA says it failed to adequately communicate the indication and limitations of use a

Take a deep dive into the future of Tandem Diabetes. In December, the company laid out an ambitious 5-year plan to update software, move to a smaller pump and ultimately a tubeless version. Company leaders say they want to think even bigger and we're talking to Chief Strategy Officer Elizabeth Gasser. We'll go through the short term changes Tandem has in the pipeline like the tiny Mobi pump and talk about philosophy and more. Tandem R&D Presentation (slides) Tandem R&D Presentation (replay) This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *DEXCOM* Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921 where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week, a deep dive into the future of Tandem diabetes. That company laid out an ambitious five-year plan to update software, move to a smaller pump and ultimately move to a tubeless version. company leaders say they want to think even bigger. Elizabeth Gasser 0:37 we have thermostats that manage our home temperature for us. We have self-driving cars we have on demand consumption services that you know, help us get our groceries and plan our meals. Come on. We should demand that level of ease of use in what we're doing here as well. Stacey Simms 0:54 That's Tandem Chief Strategy Officer Elizabeth Gasser. We'll go through the short term changes Tandem has in the pipeline like the tiny Mobi pump, she'll answer a bunch of your questions. We'll talk about the philosophy of the company moving forward, and more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, I am only so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. back in December Tandem made a big splash with their very first research and development presentation. If you haven't seen that, I highly recommend that it is rather long, but it's definitely worth checking out. I'll link that up in the show notes. And you can always find out more at diabetes connections.com. But in this R&D presentation, they laid out a very ambitious five-year plan for the company, which we're going to go through and talk about in detail today. Quick date check for you This interview was taped on January 10 2022. And we're releasing it on January 25 2022. So as of right now, the FDA has not approved anything new for Tandem no Mobile bolus that is in front of the FDA, and we'll talk about that and so much more. There were a few questions I didn't have time to get to or that you sent in after the interview. So I sent those to Tandem and I will come back after the interview. I'll update you and answer what I can also after the interview, if you are a health care provider, a diabetes educator and endocrinologist if you work in those offices. And a very specific question for you. Please come back. I'll make it quick. But I need some information. And I know you will can help me. Okay. My guest this week is Tandem Chief Strategy Officer Elizabeth Gasser she says Call me Liz. So I do. Her background isn't in diabetes, it is in strategy and corporate development, working at Qualcomm in their internet services division and at open wave systems, the world's leading Mobile browser provider at that time, and we talk about what it's like to come from that world to this one, I think it's really important to kind of get an idea for these individuals, you know who they are, who are making these decisions that affect so many of us. And of course, we go through that 10 to five year plan product by product. Liz, welcome to Diabetes Connections. Thank you so much for joining me, we have a lot to talk about today. Thanks for being here. Elizabeth Gasser 3:24 Oh, my pleasure. I'm excited to chat. Stacey Simms 3:27 There are a lot of items that Tandem announced in December, there's a lot to go through there. But I wonder if we could start kind of by backing up a little bit I've heard that you Tandem is kind of talking about being less of a hardware company, right, the pump, which will always be there in some way, shape, or form. But thinking more about the software, can we step back a little bit from the products here and talk a little bit more about kind of the philosophy or the vision? Oh, happy Elizabeth Gasser 3:53 to and if you've watched our R&D day, you'll you'll know that I do e

Every week "In the News…" brings you the top stories and headlines around the diabetes community. Top stories this week include: how new nanotechnology might help make stem cell transplants a reality (without immuosuppresive drugs), a worldwide A1C survey, the FDA releases more info about issues with Medtronic, lung function and type 2 and some info about diabetes camp. Join Stacey live on Facebook every Wednesday at 4:30pm EST and in Instagram at 4:45pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! DEXCOM Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you're new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX Looking to get organized? Check out my new guide with top tips to clear your diabetes clutter. Everything from how to start to where to donate and how to keep it from taking over your house. Head over to the home page to get organized. XX Lots of news in the last few months about stem cells and type 1.. but transplantation still means rejection without immune-suppressive drugs. Researchers at Northwestern University say they may have a way around those problems. They're using nano-carriers to generate a new form of immune-suppression that can target specific cells related to the transplant.. without suppressing wider immune responses. This paper was published in the journal Nature Nanotechnology. one of the researchers, Jacqueline Burke, was diagnosed with type 1 at age nine. She's one of the study authors and hopes it has a major impact on the future of diabetes research. https://news.northwestern.edu/stories/2022/01/nanotherapy-type-1-diabetes/ XX Possible new link between lung function and the onset of diabetes. This is a big study out of South Korea.. almost 20-thousand healthy adults followed over almost four years. At the beginning of the study none of them had diabetes. After adjusting for other factors, the team found that the group with the best lung function had a lower risk of developing diabetes. More study is needed, but these researchers think that managing lung health – which isn't really ever looked at as a risk factor - could help prevent diabetes. http://www.koreabiomed.com/news/articleView.html?idxno=12981 XX Big study of people with type 1 from 22 different countries showing that most don't have an A1C under 7.5%. As you'd imagine, that varies widely by country and by age. This was info from more than 500-thousand people gathered over 4 years. Highest A1Cs were generally in people aged 15-24 There's a lot of data here and I'll link it up. But the researchers don't seem to try to delve into what's going on or why this is the case. https://www.healio.com/news/endocrinology/20220119/hba1c-remains-suboptimal-for-most-people-with-type-1-diabetes XX It's not a surprise that hotter weather could mean more health issues for some.. but a new study from Brazil is closely watching heat and diabetes. Every 5-degree Celsius increase in daily temperature correlated with a 6-percent increase in hospitalizations due to diabetes.. this was between 2000 and 2015. The oldest patients were at an increased risk for diabetes-related hospitalization when exposed to heat. The study authors say it's the first nationwide study to look at this issue. https://www.healio.com/news/nephrology/20220118/increase-in-heat-exposure-correlates-with-increase-in-hospitalization-due-to-diabetes XX Medtronic still in a bit of hot water with the US FDA.. Medtronic took more than three years to replace and start recalling insulin pumps with defective retainer rings after first becoming aware of the problem.. this according to an FDA warning letter sent to the company in December and recently made public. The company also failed to investigate more than 800 complaints about defective updated retainer rings and failed to promptly notify the FDA within 30 days after discovering that issues with the device could lead to serious injury or death. Medtronic says, quote "We take these issues very seriously and hold ourselves to the highest standards of quality and patient safety," https://www.startribune.com/fda-medtronic-slow-to-update-recall-defective-insulin-pumps-for-diabetes-patients/600136525/ XX Medical write up of what might be the oldest person to be newly diagnosed with type 1. This was a 93-year-old woman. Her A1C was 12.9 but I didn't see in the write up why they had a high clinical suspicion of type 1. They checked her diabetes auto antibodies and confirmed the diagnosis. On recovery, she was dischar

Diagnosed almost 60 years ago, Joanne Milo loves technology and helped start the popular Loop and Learn group. She's also passionate about diabetes and aging. It's hard to believe now, but many people diagnosed in the 1960s and 70s were told they wouldn't live to age 40. Thankfully, that wasn't true. But the medical world wasn't prepared for them to actually live long and healthy lives. There is very little research or support for people with type 1 over the age of 50. Imagine when you get to 80 or beyond! Joanne Milo is also the author of the book and blog "The Savvy Diabetic" and she has a lot to say about how we can all prepare better for emergencies or hospital stays. Joanne's website - The Savvy Diabetic More about Loop and Learn This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!)

Every week "In the News..." brings you the top stories and headlines around the diabetes community. Top stories this week include: a Dexcom G7 data update, Abbott announces new Lingo sensors to measure ketones and more, it's 100 years since the first insulin shot, Lilly Diabetes discontinues T1D Everyday Magic and an ultra releases diabetes data to a medical journal -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. All sources linked up where you're watching and at Diabetes-Connections dot com when this airs as a podcast. XX Looking to get organized? Check out my new guide with top tips to clear your diabetes clutter. Everything from how to start to where to donate and how to keep it from taking over your house. Head over to diabetes-connections dot com to organize your diabetes supplies! XX Some new information about Dexcom's upcoming G7, which has been submitted to the US FDA and in Europe. Latest clinical study show the MARD of the G7 is 8.2 for adults, compared to 9 for the G6. MARD is the Mean absolute relative difference and the lower the better here. G7 was even lower, 8.1 for kids. This is close to the same results they talked about last summer, but the group in the trial was bigger. G7 is expected to get approval in Europe this quarter and likely in the US much later this year. Our last longer format interview episode is with Dexcom's CEO and we go in depth on this. https://www.drugdeliverybusiness.com/dexcom-ceo-touts-unprecedented-performance-of-g7-in-clinical-trial-awaits-fda-decision/?fbclid=IwAR3G5_Fu9fhPfR0M3FzgCNCsFYmo4gDRDy5nJySgxt56mMVJgrpUsVQedis https://investors.dexcom.com/static-files/0c3012e2-40f4-4046-a962-85e6b421d490 XX Two COVID and diabetes studies I want to talk about.. the first showing that more children are being diagnosed with type 1 and type 2 diabetes after getting COVID. This study looked at databases of people under 18 starting in March 2020 and going for 18 months. There are a LOT of questions here.. including whether post-COVID type 2 diabetes will actual be a temporary or chronic condition. Which leads us to the other study.. this one of adults, in almost 4-thousand covid patients, just under half developed high blood sugar levels, including many who were not previously diabetic. These researchers say a lot of the patients here were in their 30s and 40s, no sign of diabetes before COVID.. and the levels of glucose in their blood were incredibly high, sometimes more than twice the level that indicates diabetes. These patients still had high levels of C-peptide, which shows that they were still producing insulin. The theory here is that something is disrupting the fat cells. But the researchers admit they are just at the beginning of figuring this out. It's this latter study and others like it that seem to be showing that there really is something different about COVID and blood glucose. I saw a lot of people dismissing the children's study with, well, any virus can cause T1D. I'm glad these researchers are digging into what's going on. https://www.sciencenews.org/article/coronavirus-covid-diabetes-fat-cells-blood-sugar https://www.nytimes.com/2022/01/07/health/kids-covid-diabetes-cdc.html XX Abbott unveils plans for a new line of consumer bio-wearable sensors that will collect a broader range of biological readings to help users optimize their exercise and nutrition regimens and overall health. Called "Lingo"- which are still under development and aren't intended for medical use— they are based on the existing Freestyle Libre diabetes monitoring technology. We're talking about glucose, ketones, lactate and alcohol. Interesting to me that these were shown at the Consumer Electronics Show and not a medical conference, but Abbott is up front that these are basically for athletes and not for people with diabetes or those who need to make medical decisions based on the sensors. We'll see which of these makes it off the drawing board. https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech XX Another divestment for Lilly Diabetes – last week we told you they were doing away with their Journey Medals for diaversaries.. they have since announced that T1D everyday magic is no more. This was a partnership between Lilly and Disney that was a blog and a place for recipes and the home of those Coco books, the cute monkey with diabetes who hangs out with Mickey & Minnie Mouse. As of today you can still get digital versions of the books via the website but we'll see how long that lasts. Full

This week, Dexcom CEO Kevin Sayer spoke to the JP Morgan Healthcare Conference about the G7 and beyond. We talk about information from that presentation and get to as many of your questions as time allows. This interview took place on Tuesday Jan 11 and much of what we discussed isn't FDA approved. Dexcom presentation info here Club1921 info here Our usual disclaimer: Dexcom is a sponsor of this podcast, but they don't dictate content and they don't tell me what to ask their executives. Recent Dexcom episodes: CTO Jake Leach talks about Garmin, Dexcom One & more CEO Kevin Sayer talks about G7, Direct to Watch, Adhesive and more CEO Kevin Sayer talks about Dexcom in Hospital, G7, VA program and more Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921. Where Diabetes Connections are made This is Diabetes Connections with Stacey Simms. Welcome to another week of the show. You know I'm always so glad to have you here. We aim to educate and inspire about diabetes with a focus on people who use insulin. And I'm talking with Dexcom CEO this week, it's Kevin Sayer, he is back to check in with us again. And in the interest of getting this episode out to you as soon as I could. It might sound a little different right here at the beginning. But Dexcom episodes are always so high interest that it really merits a quick turnaround. I didn't want to sit on this interview for a week. So here's the setup. Dexcom CEO Kevin Sayer gave a presentation to the JP Morgan healthcare conference, if you're listening as this episode goes live, that was just Monday of this week, January 10, the interview you're about to hear took place on Tuesday, January 11. My usual disclaimer Dexcom is a sponsor of this podcast, but they don't dictate content and they don't tell me what to ask their executives. I asked the Diabetes Connections podcast Facebook group for questions. And Whoa, boy, did you have a lot as always not a surprise. And I really appreciate you sending those in, I got to as many as I could, while also trying to include what the folks at Dexcom had really asked me to bring up there are some topics that they wanted Kevin to make sure to address. And I think we do a pretty good job of trying to reach a balance here. Kevin, welcome and Happy New Year, Kevin Sayer 1:46 and Happy New Year to you. Stacey Simms 1:48 Thank you. Well, this seems to have started out in pretty happy way on the headline, just from this week. Dexcom CEO touts unprecedented performance of G7 in clinical trial. This is after your talk at the annual JP Morgan healthcare conference. Tell me a little bit about that unprecedented performance data. Kevin Sayer 2:08 I'm happy to. And I just have to qualify it by saying no, I can't send it to all your listeners at the end of the call yet. We're still waiting for approval in Europe. And we have filed this with the FDA, I'm going to take you back a little bit, we made a decision when we were going through the G7 development process that we wanted to answer that performed better than G6. And all of our scientists looked at us and they go oh, really, you're sure because this is really good. And so we spent a lot of time new algorithms and new manufacturing techniques, there's a lot of things in G7 that make it different. We also wanted to validate that performance with a study that was so large, nobody could refute it. So as you look at the data that I presented at the conference yesterday, over 300 patients 39,000 Match pairs all across since one ranges and on the I CGM standard side, but with the 5% 95% lower bound, and even the absolute points, you can see we are well within all of the iCGM standards, which are very technical and actually are a very good measure of how a sensor actually performs in reality. And they were very thoughtful in developing these standards to try and pick the centers that don't work to put you statistically in a bind to whereby if you really aren't performing in the low range or wherever, you're not going to get that iCGM designation. We're very comfortably there. And the overall MARD in the study, Stacey is eight point, you know I it's in the low eight for adults and pediatrics. And if you start looking at the data, we gather the data sets in three periods, you know, days one and two, the middle days, four, or five and six, and the last days nine and 10. It's pretty low, I think it's below 10. In the first group a day, the first days, which are always a little bit higher, traditionally in our centers than the other days. But in those middle and end days, it's it's near seven, and strips for six. I mean,

In the News... top stories this week: A second glucose-regulating molecule discovered, CGM use closer to diagnosis helps T1D kids, Lilly discontinues "Journey Awards," study on Dexcom use in hospitals, and why does this concept car share a diabetes tech name? -- Join us LIVE every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. All sources linked up on our Facebook Page and at Diabetes-Connections dot com when this airs as a podcast. XX In the News is brought to you by The World's Worst Diabetes Mom, Real life stories of raising a child with diabetes. Winner of the American Book Fest Prize for best new non-fiction. Available in paperback, on Kindle or as an audio book – all at Amazon.com. XX Our top story.. You know insulin helps regulate blood glucose. Now scientists have discovered a second molecule in the body that seems to do the same thing. It's produced by fat tissue but uses a different molecular pathway.. so it's hopeful this could get around insulin resistance. These scientists say the hormone, called F-G-F-1 suppresses breakdown of fat cells into free fatty acids and regulates the production of glucose in the liver. Because it does this in a different way from insulin, they're calling it a second loop. Very early here but very intriguing. XX New study out of Stanford says setting children and teens up with a CGM shortly after a T1D diagnosis.. results in a lower A1C a year later. They looked at kids diagnosed in 2018 to 2020… and compared that group to other children diagnosed four years earlier. In that first group, about 90-percent started CGM in the first month.. in second group it was under 2-percent that started that early. At diagnosis, the children in the newer cohort had higher A1c s. At 6 months and 12 months after diagnosis, the patients in the new cohort had significantly lower A1Cs than the other kids. These researchers say the news is more evidence to get insurers to cover the devices. https://healthier.stanfordchildrens.org/en/kids-early-use-of-diabetes-technology/ XX A new risk factor for type 2 mostly affects women, and it's in about 10-percent of the population. A new study says about one in 10 adults has a lump in their adrenal glands that, though otherwise harmless, increases production of certain hormones that increase the risk for Type 2 and high blood pressure. About 70% of those with them were women, most of whom were 50 years old or older. It's called mild autonomous cortisol secretion and these researchers say we should start screening for it. https://www.upi.com/Health_News/2022/01/03/adrenal-tumor-diabetes-blood-pressure-study/2471641237308/XX XX After almost 50 years of honoring people with diabetes with anniversary medals, Lilly Diabetes is phasing out the Journey Awards. Awards were given to patients for 10, 25, 50 and 75 years. A Lilly spokesperson confirmed the news to me today.. saying "We periodically need to re-assess and prioritize programs as the environment and our business shifts. We believe our decision will allow us to focus on programs that we hope bring the most value to people living with diabetes." They encourage people to check out the Joslin Medalist program and I'll link that up. Joslin.org/research/our-research/medalist-program-study XX Movement on a couple of court cases involving insulin makers. Sanofi lost its appeals court bid to revive patents on Lantus. You'll recall that last year, Viatris got approval for Semglee, it's long-acting insulin, which is basically the same thing and is approved for the same indications as Lantus. Sanofi is facing an antitrust lawsuit accusing it of obtaining some 20 patents in an effort to delay competition. Viatris has been knocking out the patents in court. https://www.bloomberg.com/news/articles/2021-12-29/sanofi-loses-bid-to-revive-lantus-solostar-insulin-pen-patents XX A federal judge has pared down a class action lawsuit accusing the biggest insulin makers of racketeering. Novo Nordisk, Sanofi and Eli Lilly are accused of scheming together to inflate prices. However, the US District Judge ruled that claims under the racketeering laws of several states (except for Arizona's) must be dismissed… because the laws do not allow claims by plaintiffs who bought the drugs through intermediaries, such as insurance companies, rather than from the drugmakers directly. The same judge did allow these RICO claims to proceed earlier this year in a separate class action against the companies brought by direct purchasers. https://www.reuters.com/legal/litigation/sanofi-lilly-escape-state-racketeering-charges-insulin-price-b

Diabetes on TV and in movies is rarely anything close to accurate. Turns out, those media misconceptions can be real-life harmful. This week, Stacey is joined by Dr. Heather Walker, the co-author of (Un)Doing Diabetes: Representation, Disability, Culture and Dr. Phyllisa Deroze, who contributed a chapter called "Laughing to Keep From Dying: Black Americans with Diabetes in Sitcoms and Comedies. Dr. Deroze & Dr. Walker both live with type 1 and both have difficult diagnosis stories that influenced their experiences with diabetes going forward. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Dr. Phyllisa Deroze More about Dr. Heather Walker ---- Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode Transcription: Stacey Simms 0:00 Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom. This is Diabetes Connections with Stacey Simms. This week, diabetes on TV and in the movies is rarely anything close to accurate. And those media misconceptions can be real life harmful. Here's one from the sitcom 30 Rock. Dr. Phyllisa Deroze 0:30 Tracy has diabetes there. And he does this skit where he replaces his foot with a skate. And he's like I'm practicing for when I lose my foot to diabetes. And that is the thing. There was a diabetes diagnosis and the next scene, he's already imagining himself with an amputation. Stacey Simms 0:49 That's Dr. Phyllisa Deroze, who wrote a chapter in a new book we're talking about this week. The book is called (Un)Doing Diabetes Representation, Disability Culture. And it's authored by Dr. Heather Walker, Dr. Deroze and Dr. Walker both live with type one, and they join me for a great conversation. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, I am always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. This is our first show of 2022. So Happy New Year, everybody. I hope you're doing okay. Still stressful days for everybody. But hopefully you can kind of come along with me every week, as we talk about what we're finding interesting in the diabetes community. And I say that because 2021, I decided I was going to focus on technology for the year, I was going to try to do as many episodes as I could, talking about new technology talking to these companies. And I did that although I gotta say the log jam at the FDA made that a little difficult, right? I mean, we thought we'd have a lot more new technology. And a lot of companies will not talk about stuff until it is FDA approved. So this year, I'm going to stay with that because the technology episodes are what you have told me you are the most interested in, in fingers crossed are going to have some approvals pretty soon. But I gotta tell you, I've also decided that I'm going to do shows on just whatever the heck I find interesting. I started this show seven years ago, this coming summer, and honestly, this might be the last year of it in this form. I mean, I love it. I love doing this but seven years is a long time for any project. I have some new things that I'm working on. I'm not sure how much time all of it is going to take. I'm not abandoning the podcast by any means. I want to hear from you too. As we go forward. You know, as the year goes by, I will keep the lines of communication open. We will figure it out together. This episode does fall into the category of something I am fascinated by and I love to talk about and that is diabetes in media. And by the way separately. Both of my guests this week have bananas misdiagnosis stories, we get to that right out of the gate. Wait till you hear what one of their doctors ended up doing. I have never heard this happening before. It was pretty wild. And we will talk about the book I mentioned that it is (Un)Doing Diabetes Representation, Disability Culture. It is authored by Dr. Heather Walker and Dr. Dr. Bianca C. Frazer. It contains essays by other authors including Dr. Phyllisa Deroze a little bit more about the book in its public description. It says undoing diabetes is the first collection of essays to use disability studies to explore representations of diabetes across a wide range of mediums from Twitter to TV and film to theater fiction, fan fiction, fashion and more. In undoing diabetes Authors deconstruct assumptions the public commonly holds while writers doing diabetes present counter narratives community members create to

Our top stories this week include Medicare further expanding CGM coverage, Beta Bionics has an iLet update, ADA announces new Standards of Care, a new study looks at using Fitbits to predict the risk of type 2, and more! Join us LIVE on Facebook every Wednesday at 4:30pm EST Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode transcription below: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. As always, I'm going to link up my sources in the Facebook comments – where we are live – we are also Live on YouTube and in the show notes at d-c dot com when this airs as a podcast.. XX In the News is brought to you by The World's Worst Diabetes Mom, Real life stories of raising a child with diabetes. Winner of the American Book Fest Prize for best new non-fiction. Available in paperback, on Kindle or as an audio book – all at Amazon.com. XX Our top story.. another adjustment for CGM coverage under Medicare. All types of continuous glucose monitors will now be included. The difference here is that it includes CGMs that aren't approved for making decisions about insulin dosing – at this point, that's really just the Medtronic brand. This follows another decision in July that covered CGM use with any insulin – including inhaled insulin - and got rid of the four times per day fingerstick testing requirements. The new rule goes into effect in two months. https://www.healio.com/news/endocrinology/20211222/cms-expands-medicare-coverage-for-all-cgms XX The American Diabetes Association is out with its annual Standards of Medical Care in Diabetes. Notable updates include: Screening for prediabetes and diabetes beginning at age 35 for all people; Changes to gestational diabetes recommendations regarding when to test and who to test. Updated recommendations on technology selection based on individual and caregiver considerations, ongoing education on use of devices, continued access to devices across insurance companies, support of students using devices in school, use of telehealth visits, and early initiation of technology. https://www.prnewswire.com/news-releases/latest-ada-annual-standards-of-care-includes-changes-to-diabetes-screening-first-line-therapy-pregnancy-and-technology-301448533.html XX Little bit of news from Beta Bionics, makers of the iLet Bionic Pancreas System. They've completed a randomized controlled trial for their insulin only pump.. this included 440 adults and kids over the age of 6 with type 1. The iLet is different in that you only put your weight in and the system learns you. No carb ratios or basal rates. You do still announce meals, but no carb counting.. just meal size. Public presentation of the clinical data is expected in the first half of 2022. They're now enrolling into the screening protocol for the next step, the pivotal trial for their Bihormonal pump that would use insulin and glucagon. https://www.globenewswire.com/news-release/2021/12/22/2356645/0/en/Beta-Bionics-Announces-Data-Lock-of-the-Insulin-Only-Bionic-Pancreas-Pivotal-Trial-and-Enrollment-into-the-Screening-Protocol-of-the-Bihormonal-Bionic-Pancreas-Pivotal-Trial.html XX You probably know there is a terrible shortage of endocrinologists in this country.. an estimated 80% patients with diabetes use their primary physician's office for their diabetes care. There's a new push for more endo fellowships.. These 1-year programs, with funding and accreditation, train interested family and internal medicine clinicians in intensive diabetes management. There are several in existence but there's a new white paper on this getting a lot of buzz. However, critics say it would be a drop in the bucket and couldn't graduate enough endos to make a difference. Everyone agrees that the problem needs to be addressed. https://www.healio.com/news/endocrinology/20211229/endocrinologists-propose-diabetes-fellowship-programs-to-address-growing-gap-in-care XX Interesting study on the use of health wearables and changes in blood sugar. Wearables here refers to Fitbits, so they're tracking activity not blood glucose. These researchers say their models can accurately identify changes in glycemic control among prediabetic adults, and this could be used to better allocate resources and target interventions to prevent progression to diabetes. Interestingly, the wrist wearable seemed to work better for people than the waist kind. Not a big surprise when you think about which is more popular for use outside of studies. Anybody use a waist wearable anymore? Let me know. https://www.nature.com/articles/s41746-021-00541-1 XX And finally.. a Te